

1 **Medical Cannabis Program Amendments**

2026 GENERAL SESSION

STATE OF UTAH

**Chief Sponsor: Evan J. Vickers**

House Sponsor: Walt Brooks

---

2  
3 **LONG TITLE**

4 **General Description:**

5 This bill amends provisions related to the medical cannabis program.

6 **Highlighted Provisions:**

7 This bill:

- 8 ▶ defines terms;
- 9 ▶ amends when the Cannabis Production Establishment and Pharmacy Licensing Advisory

10 Board must meet to review an ownership change application;

- 11 ▶ amends provisions related to labeling of cannabis products;
- 12 ▶ amends provisions related to cannabis remediation;
- 13 ▶ repeals language related to electronic payments;

14 ▶ enacts provisions related to the safe storage of medical cannabis for medical cannabis  
15 deliveries;

16 ▶ amends provisions related to when a medical cannabis pharmacy agent may access the  
17 electronic verification system;

18 ▶ amends provisions related to acceptable forms of identification;

19 ▶ amends provisions related to the revocation of certain medical cannabis agent cards;

20 ▶ allows a medical cannabis guardian card to be issued to the legal guardian of an adult who  
21 is incapacitated;

22 ▶ extends the repeal of the medical cannabis governance structure working group; and

23 ▶ makes technical and conforming changes.

24 **Money Appropriated in this Bill:**

25 None

26 **Other Special Clauses:**

27 None

28 **Utah Code Sections Affected:**

29 AMENDS:

30 **4-41a-201**, as last amended by Laws of Utah 2025, Chapter 414

31 **4-41a-501**, as last amended by Laws of Utah 2025, Chapter 114  
 32 **4-41a-602**, as last amended by Laws of Utah 2025, Chapter 392  
 33 **4-41a-1001**, as last amended by Laws of Utah 2025, Chapters 114, 277 and 414  
 34 **4-41a-1101**, as last amended by Laws of Utah 2025, Chapter 392  
 35 **4-41a-1106**, as last amended by Laws of Utah 2025, Chapter 414  
 36 **4-41a-1201**, as last amended by Laws of Utah 2025, Chapter 114  
 37 **4-41a-1204**, as last amended by Laws of Utah 2025, Chapter 414  
 38 **4-41a-1205**, as last amended by Laws of Utah 2023, Chapter 317 and renumbered and  
 39 amended by Laws of Utah 2023, Chapters 273, 307 and last amended by Coordination Clause,  
 40 Laws of Utah 2023, Chapter 307  
 41 **26B-1-421**, as last amended by Laws of Utah 2025, Chapter 494  
 42 **26B-4-201**, as last amended by Laws of Utah 2025, Chapter 392  
 43 **26B-4-202**, as last amended by Laws of Utah 2025, Chapter 392  
 44 **26B-4-213**, as last amended by Laws of Utah 2025, Chapter 392  
 45 **26B-4-214**, as last amended by Laws of Utah 2025, Chapter 392  
 46 **63I-2-236**, as last amended by Laws of Utah 2025, Chapters 277, 414

---

48 *Be it enacted by the Legislature of the state of Utah:*

49 Section 1. Section **4-41a-201** is amended to read:

50 **4-41a-201 . Cannabis production establishment -- License.**

51 (1) Except as provided in Subsection (14), a person may not operate a cannabis production  
 52 establishment without a license that the department issues under this chapter.

53 (2)(a)(i) Subject to Subsections (6), (7), (8), and (13) and to Section 4-41a-205, for a  
 54 licensing process that the department initiates after March 17, 2021, the  
 55 department, through the licensing board, shall issue licenses in accordance with  
 56 Section 4-41a-201.1.

57 (ii) In accordance with Title 63G, Chapter 3, Utah Administrative Rulemaking Act,  
 58 the department shall make rules to specify a transparent and efficient process to:

59 (A) solicit applications for a license under this section;

60 (B) allow for comments and questions in the development of applications;

61 (C) timely and objectively evaluate applications;

62 (D) hold public hearings that the department deems appropriate; and

63 (E) select applicants to receive a license.

64 (iii) The department may not issue a license to operate a cannabis production

- 65 establishment to an applicant who is not eligible for a license under this section.
- 66 (b) An applicant is eligible for a license under this section if the applicant submits to the  
67 licensing board:
- 68 (i) subject to Subsection (2)(c), a proposed name and each address, located in a zone  
69 described in Subsection 4-41a-406(2)(a) or (b), where the applicant will operate  
70 the cannabis production establishment;
- 71 (ii) the name and address of any individual who has:
- 72 (A) for a publicly traded company, a financial or voting interest of 10% or greater  
73 in the proposed cannabis production establishment;
- 74 (B) for a privately held company, a financial or voting interest in the proposed  
75 cannabis production establishment; or
- 76 (C) the power to direct or cause the management or control of a proposed cannabis  
77 production establishment;
- 78 (iii) an operating plan that:
- 79 (A) complies with Section 4-41a-204;
- 80 (B) includes operating procedures that comply with this chapter and any law the  
81 municipality or county in which the person is located adopts that is consistent  
82 with Section 4-41a-406; and
- 83 (C) the department or licensing board approves;
- 84 (iv) a statement that the applicant will obtain and maintain a liquid cash account with  
85 a financial institution or a performance bond that a surety authorized to transact  
86 surety business in the state issues in an amount of at least:
- 87 (A) \$100,000 for each cannabis cultivation facility for which the applicant applies;  
88 or
- 89 (B) \$50,000 for each cannabis processing facility or independent cannabis testing  
90 laboratory for which the applicant applies;
- 91 (v) an application fee in an amount that, subject to Subsection 4-41a-104(5), the  
92 department sets in accordance with Section 63J-1-504; and
- 93 (vi) a description of any investigation or adverse action taken by any licensing  
94 jurisdiction, government agency, law enforcement agency, or court in any state for  
95 any violation or detrimental conduct in relation to any of the applicant's  
96 cannabis-related operations or businesses.
- 97 (c)(i) A person may not locate a cannabis production establishment:
- 98 (A) within 1,000 feet of a community location; or

- 99 (B) in or within 600 feet of a district that the relevant municipality or county has  
100 zoned as primarily residential.
- 101 (ii) The proximity requirements described in Subsection (2)(c)(i) shall be measured  
102 from the nearest entrance to the cannabis production establishment by following  
103 the shortest route of ordinary pedestrian travel to the property boundary of the  
104 community location or residential area.
- 105 (iii) The licensing board may grant a waiver to reduce the proximity requirements in  
106 Subsection (2)(c)(i) by up to 20% if the licensing board determines that it is not  
107 reasonably feasible for the applicant to site the proposed cannabis production  
108 establishment without the waiver.
- 109 (iv) An applicant for a license under this section shall provide evidence of  
110 compliance with the proximity requirements described in Subsection (2)(c)(i).
- 111 (3) If the licensing board approves an application for a license under this section and  
112 Section 4-41a-201.1:
- 113 (a) the applicant shall pay the department an initial license fee in an amount that, subject  
114 to Subsection 4-41a-104(5), the department sets in accordance with Section 63J-1-504;  
115 and
- 116 (b) the department shall notify the Department of Public Safety of the license approval  
117 and the names of each individual described in Subsection (2)(b)(ii).
- 118 (4)(a) Except as provided in this Subsection (4), a cannabis production establishment  
119 shall obtain a separate license for each type of cannabis production establishment and  
120 each location of a cannabis production establishment.
- 121 (b) The licensing board may issue a cannabis cultivation facility license and a cannabis  
122 processing facility license to a person to operate at the same physical location or at  
123 separate physical locations.
- 124 (c) A cannabis cultivation facility may operate at two addresses under a single license.
- 125 (d) A tier one cannabis processing facility may operate at a second address under the  
126 same tier one license if:
- 127 (i) the second address is co-located at a cannabis cultivation facility operated by the  
128 same licensee; and
- 129 (ii) the licensee pays a fee of \$70,000 for the second location.
- 130 (e) An applicant for a tier two cannabis processing facility license that has a cannabis  
131 cultivation facility license and intends to process cannabis at the cannabis cultivation  
132 facility shall pay a fee of \$25,000 for the tier two cannabis processing facility license.

- 133 (5) If the licensing board receives more than one application for a cannabis production  
134 establishment within the same city or town, the licensing board shall consult with the  
135 local land use authority before approving any of the applications pertaining to that city  
136 or town.
- 137 (6) The licensing board may not issue a license to operate an independent cannabis testing  
138 laboratory to a person who:
- 139 (a) holds a license or has an ownership interest in a medical cannabis pharmacy, a  
140 cannabis processing facility, or a cannabis cultivation facility;
- 141 (b) has an owner, officer, director, or employee whose family member holds a license or  
142 has an ownership interest in a medical cannabis pharmacy, a cannabis processing  
143 facility, or a cannabis cultivation facility; or
- 144 (c) proposes to operate the independent cannabis testing laboratory at the same physical  
145 location as a medical cannabis pharmacy, a cannabis processing facility, or a  
146 cannabis cultivation facility.
- 147 (7) The licensing board may not issue a license to operate a cannabis production  
148 establishment to an applicant if any individual described in Subsection (2)(b)(ii):
- 149 (a) has been convicted under state or federal law of:
- 150 (i) a felony in the preceding 10 years; or
- 151 (ii) after December 3, 2018, a misdemeanor for drug distribution;
- 152 (b) is younger than 21 years old; or
- 153 (c) after September 23, 2019, until January 1, 2023, is actively serving as a legislator.
- 154 (8)(a) If an applicant for a cannabis production establishment license under this section  
155 holds a license under [~~Title 4,~~] Chapter 41, Hemp and Cannabinoid Act, the licensing  
156 board may not give preference to the applicant based on the applicant's status as a  
157 holder of the license.
- 158 (b) If an applicant for a license to operate a cannabis cultivation facility under this  
159 section holds a license to operate a medical cannabis pharmacy under this title, the  
160 licensing board may give consideration to the applicant based on the applicant's  
161 status as a holder of a medical cannabis pharmacy license if:
- 162 (i) the applicant demonstrates that a decrease in costs to patients is more likely to  
163 result from the applicant's vertical integration than from a more competitive  
164 marketplace; and
- 165 (ii) the licensing board finds multiple other factors, in addition to the existing license,  
166 that support granting the new license.

- 167 (9) The licensing board may revoke a license under this part:
- 168 (a) if the cannabis production establishment does not begin cannabis production
- 169 operations within one year after the day on which the licensing board issues the
- 170 initial license;
- 171 (b) after the third of the same violation of this chapter in any of the licensee's licensed
- 172 cannabis production establishments or medical cannabis pharmacies;
- 173 (c) if any individual described in Subsection (2)(b) is convicted, while the license is
- 174 active, under state or federal law of:
- 175 (i) a felony; or
- 176 (ii) after December 3, 2018, a misdemeanor for drug distribution;
- 177 (d) if the licensee fails to provide the information described in Subsection (2)(b)(vi) at
- 178 the time of application, or fails to supplement the information described in
- 179 Subsection (2)(b)(vi) with any investigation or adverse action that occurs after the
- 180 submission of the application within 14 calendar days after the licensee receives
- 181 notice of the investigation or adverse action;
- 182 (e) if the cannabis production establishment demonstrates a willful or reckless disregard
- 183 for the requirements of this chapter or the rules the department makes in accordance
- 184 with this chapter;
- 185 (f) if, after a change of ownership described in Subsection (15)(b), the board determines
- 186 that the cannabis production establishment no longer meets the minimum standards
- 187 for licensure and operation of the cannabis production establishment described in this
- 188 chapter;
- 189 (g) for an independent cannabis testing laboratory, if the independent cannabis testing
- 190 laboratory fails to substantially meet the performance standards described in
- 191 Subsection (14)(b); or
- 192 (h) if, following an investigation conducted pursuant to Subsection 4-41a-201.1(11), the
- 193 board finds that the licensee has participated in an anticompetitive business practice.
- 194 (10)(a) A person who receives a cannabis production establishment license under this
- 195 chapter, if the municipality or county where the licensed cannabis production
- 196 establishment will be located requires a local land use permit, shall submit to the
- 197 licensing board a copy of the licensee's approved application for the land use permit
- 198 within 120 days after the day on which the licensing board issues the license.
- 199 (b) If a licensee fails to submit to the licensing board a copy of the licensee's approved
- 200 land use permit application in accordance with Subsection (10)(a), the licensing

- 201 board may revoke the licensee's license.
- 202 (11) The department shall deposit the proceeds of a fee that the department imposes under  
203 this section into the Qualified Production Enterprise Fund.
- 204 (12) The department shall begin accepting applications under this part on or before January  
205 1, 2020.
- 206 (13)(a) The department's authority, and consequently the licensing board's authority, to  
207 issue a license under this section is plenary and is not subject to review.
- 208 (b) Notwithstanding Subsection [~~(2)(a)(ii)(A)~~] (2)(a)(i), the decision of the department to  
209 award a license to an applicant is not subject to:
- 210 (i) Title 63G, Chapter 6a, Part 16, Protests; or  
211 (ii) Title 63G, Chapter 6a, Part 17, Procurement Appeals Board.
- 212 (14)(a) Notwithstanding this section, the department:
- 213 (i) may operate or partner with a research university to operate an independent  
214 cannabis testing laboratory;
- 215 (ii) if the department operates or partners with a research university to operate an  
216 independent cannabis testing laboratory, may not cease operating or partnering  
217 with a research university to operate the independent cannabis testing laboratory  
218 unless:
- 219 (A) the department issues at least two licenses to independent cannabis testing  
220 laboratories; and
- 221 (B) the department has ensured that the licensed independent cannabis testing  
222 laboratories have sufficient capacity to provide the testing necessary to support  
223 the state's medical cannabis market; and
- 224 (iii) after ceasing department or research university operations under Subsection  
225 (14)(a)(ii) shall resume independent cannabis testing laboratory operations at any  
226 time if:
- 227 (A) fewer than two licensed independent cannabis testing laboratories are  
228 operating; or
- 229 (B) the licensed independent cannabis testing laboratories become, in the  
230 department's determination, unable to fully meet the market demand for testing.
- 231 (b)(i) The department shall make rules, in accordance with Title 63G, Chapter 3,  
232 Utah Administrative Rulemaking Act, to establish performance standards for the  
233 operation of an independent cannabis testing laboratory, including deadlines for  
234 testing completion.

- 235 (ii) A license that the department issues to an independent cannabis testing laboratory  
236 is contingent upon substantial satisfaction of the performance standards described  
237 in Subsection (14)(b)(i), as determined by the board.
- 238 (15)(a) A cannabis production establishment license is not transferrable or assignable.
- 239 (b) If the ownership of a cannabis production establishment changes by 50% or more:
- 240 (i) the cannabis production establishment shall submit a new application described in  
241 Subsection (2)(b), subject to Subsection (2)(c);
- 242 (ii) within [30] 60 days of the submission of the application, the board shall:
- 243 (A) conduct the application review described in Section 4-41a-201.1; and
- 244 (B) award a license to the cannabis production establishment for the remainder of  
245 the term of the cannabis production establishment's license before the  
246 ownership change if the cannabis production establishment meets the minimum  
247 standards for licensure and operation of the cannabis production establishment  
248 described in this chapter; and
- 249 (iii) if the board approves the license application, notwithstanding Subsection (3), the  
250 cannabis production establishment shall pay a license fee that the department sets  
251 in accordance with Section 63J-1-504 in an amount that covers the board's cost of  
252 conducting the application review.

253 Section 2. Section **4-41a-501** is amended to read:

254 **4-41a-501 . Cannabis cultivation facility -- Operating requirements.**

- 255 (1) A cannabis cultivation facility shall ensure that any cannabis growing at the cannabis  
256 cultivation facility is not visible from the ground level of the cannabis cultivation facility  
257 perimeter.
- 258 (2) A cannabis cultivation facility shall use a unique identifier that is connected to the  
259 facility's inventory control system to identify:
- 260 (a) beginning at the time a cannabis plant is eight inches tall and has a root ball, each  
261 cannabis plant;
- 262 (b) each unique harvest of cannabis plants;
- 263 (c) each batch of cannabis the facility transfers to a medical cannabis pharmacy, a  
264 cannabis processing facility, or an independent cannabis testing laboratory; and
- 265 (d) any excess, contaminated, or deteriorated cannabis of which the cannabis cultivation  
266 facility disposes.
- 267 (3) A cannabis cultivation facility shall identify cannabis biomass as cannabis byproduct or  
268 cannabis plant product before transferring the cannabis biomass from the facility.

- 269 (4) A cannabis cultivation facility shall either:
- 270 (a) ensure that a cannabis processing facility chemically or physically processes
- 271 cannabis cultivation byproduct to produce a cannabis concentrate for incorporation
- 272 into cannabis derivative products; or
- 273 (b) destroy cannabis cultivation byproduct in accordance with Section 4-41a-405.
- 274 (5)(a) A cannabis cultivation facility may ~~utilize radiation-based methods and~~
- 275 ~~equipment] , for quality assurance or remediation purposes, use methods and~~
- 276 ~~equipment as approved by the department through rule.~~
- 277 (b) The department shall allow the use of radiation-based methods and equipment in
- 278 rules created under Subsection (5)(a).
- 279 (6) The department shall make rules establishing:
- 280 (a) the records a cannabis cultivation facility must keep regarding each batch, amount of
- 281 product treated, and the methods used; and
- 282 (b) disclosure requirements to a cannabis processor receiving the material subject to the
- 283 radiation including the methods and equipment used.
- 284 Section 3. Section **4-41a-602** is amended to read:
- 285 **4-41a-602 . Cannabis product -- Labeling and child-resistant packaging.**
- 286 (1) For any cannabis product that a cannabis processing facility processes or produces and
- 287 for any raw cannabis that the facility packages, the facility shall:
- 288 (a) label the cannabis or cannabis product with a label that:
- 289 (i) clearly and unambiguously states that the cannabis product or package contains
- 290 cannabis;
- 291 (ii) clearly displays the amount of total composite tetrahydrocannabinol, cannabidiol,
- 292 and any known cannabinoid that is greater than 1% of the total cannabinoids
- 293 contained in the cannabis or cannabis product as determined under Subsection
- 294 4-41a-701(4);
- 295 (iii) has a unique identification number that:
- 296 (A) is connected to the inventory control system; and
- 297 (B) identifies the unique cannabis product manufacturing process the cannabis
- 298 processing facility used to manufacture the cannabis product;
- 299 (iv) identifies the cannabinoid extraction process that the cannabis processing facility
- 300 used to create the cannabis product;
- 301 (v) does not display an image, word, or phrase that the facility knows or should know
- 302 appeals to children; and

- 303 (vi) discloses each active or potentially active ingredient, in order of prominence, and  
304 possible allergen; and
- 305 (b) package the raw cannabis or cannabis product in a medicinal dosage form in a  
306 container that:
- 307 (i) is tamper evident and tamper resistant;
- 308 (ii) does not appeal to children;
- 309 (iii) does not mimic a candy container;
- 310 (iv) complies with child-resistant effectiveness standards that the United States  
311 Consumer Product Safety Commission establishes;
- 312 (v) includes a warning label that states:
- 313 (A) for a container labeled on or after January 1, 2024, "WARNING: Cannabis  
314 has intoxicating effects, may be addictive, and may increase risk of mental  
315 illness. Do not operate a vehicle or machinery under its influence. KEEP OUT  
316 OF REACH OF CHILDREN. This product is for medical use only. Use only as  
317 directed by a recommending medical provider."; or
- 318 (B) for a container labeled on or after January 1, 2026, "WARNING: Cannabis  
319 use by pregnant or breastfeeding women, may result in fetal injury, preterm  
320 birth, or developmental problems for the child. Cannabis may be addictive and  
321 may increase risk of mental illness. Do not operate a vehicle or machinery  
322 under its influence. KEEP OUT OF REACH OF CHILDREN. This product is  
323 for medical use only. Use only as directed by a recommending medical  
324 provider."; and
- 325 (vi) for raw cannabis or a cannabis product sold in a vaporizer cartridge labeled on or  
326 after May 3, 2023, includes a warning label that states:
- 327 (A) "WARNING: Vaping of cannabis-derived products has been associated with  
328 lung injury."; and
- 329 (B) "WARNING: Inhalation of cannabis smoke has been associated with lung  
330 injury.".
- 331 (2)(a) ~~[Fø]~~ Except as provided in Subsection (2)(b), to ensure that a cannabis product  
332 that a cannabis processing facility processes or produces has a medical rather than  
333 recreational disposition, the facility may not produce or process a product whose  
334 logo, product name, or brand name includes terms related to recreational marijuana,  
335 including "weed," "pot," "reefer," "grass," "hash," "ganja," "Mary Jane," "high,"  
336 "haze," "stoned," "joint," "bud," "smoke," "euphoria," "dank," "doobie," "kush,"

- 337 "frost," "cookies," "rec," "bake," "blunt," "combust," "bong," "budtender," "dab,"  
 338 "blaze," "toke," or "420."
- 339 (b) A product name may contain the word "hash."
- 340 (3) For any cannabis or cannabis product that the cannabis processing facility processes into  
 341 a gelatinous cube, gelatinous rectangular cuboid, or lozenge in a cube or rectangular  
 342 cuboid shape, the facility shall:
- 343 (a) ensure that the label described in Subsection (1)(a) does not contain a photograph or  
 344 other image of the content of the container; and
- 345 (b) include on the label described in Subsection (1)(a) a warning about the risks of  
 346 over-consumption.
- 347 (4) For any cannabis product that contains an artificially derived cannabinoid, the cannabis  
 348 processing facility shall ensure that the label clearly:
- 349 (a) identifies each artificially derived cannabinoid; and
- 350 (b) identifies that each artificially derived cannabinoid is an artificially derived  
 351 cannabinoid.
- 352 (5) In accordance with Title 63G, Chapter 3, Utah Administrative Rulemaking Act, the  
 353 department:
- 354 (a) shall make rules to establish:
- 355 (i) a standard labeling format that:
- 356 (A) complies with the requirements of this section; and
- 357 (B) ensures inclusion of a pharmacy label; and
- 358 (ii) additional requirements on packaging for cannabis and cannabis products to  
 359 ensure safety and product quality; ~~and~~
- 360 (b) may make rules to further define standards regarding images, words, phrases, or  
 361 containers that may appeal to children under Subsection (1)(a)(v) or (1)(b)(ii)[-] ; and
- 362 (c) may make rules to regulate the use of common terms describing a potential  
 363 physiological effect on medical cannabis labels.
- 364 Section 4. Section **4-41a-1001** is amended to read:
- 365 **4-41a-1001 . Medical cannabis pharmacy -- License -- Eligibility.**
- 366 (1) A person may not:
- 367 (a) operate as a medical cannabis pharmacy without a license that the department issues  
 368 under this part;
- 369 (b) obtain a medical cannabis pharmacy license if obtaining the license would cause the  
 370 person to exceed the pharmacy ownership limit;

- 371 (c) obtain a partial ownership share of a medical cannabis pharmacy if obtaining the  
372 partial ownership share would cause the person to exceed the pharmacy ownership  
373 limit; or
- 374 (d) enter into any contract or agreement that allows the person to directly or indirectly  
375 control the operations of a medical cannabis pharmacy if the person's control of the  
376 medical cannabis pharmacy would cause the person to effectively exceed the  
377 pharmacy ownership limit.
- 378 (2)(a)(i) Subject to Subsections (4) and (5) and to Section 4-41a-1005, the licensing  
379 board shall issue a license to operate a medical cannabis pharmacy.
- 380 (ii) The licensing board may not issue a license to operate a medical cannabis  
381 pharmacy to an applicant who is not eligible for a license under this section.
- 382 (b) An applicant is eligible for a license under this section if the applicant submits to the  
383 licensing board:
- 384 (i) subject to Subsection (2)(c), a proposed name and address where the applicant will  
385 operate the medical cannabis pharmacy;
- 386 (ii) the name and address of an individual who:
- 387 (A) for a publicly traded company, has a financial or voting interest of 10% or  
388 greater in the proposed medical cannabis pharmacy;
- 389 (B) for a privately held company, a financial or voting interest in the proposed  
390 medical cannabis pharmacy; or
- 391 (C) has the power to direct or cause the management or control of a proposed  
392 medical cannabis pharmacy;
- 393 (iii) for each application that the applicant submits to the department, a statement  
394 from the applicant that the applicant will obtain and maintain:
- 395 (A) a performance bond in the amount of \$100,000 issued by a surety authorized  
396 to transact surety business in the state; or
- 397 (B) a liquid cash account in the amount of \$100,000 with a financial institution;
- 398 (iv) an operating plan that:
- 399 (A) complies with Section 4-41a-1004;
- 400 (B) includes operating procedures to comply with the operating requirements for a  
401 medical cannabis pharmacy described in this part and with a relevant municipal  
402 or county law that is consistent with Section 4-41a-1106; and
- 403 (C) the department approves;
- 404 (v) an application fee in an amount that, subject to Subsection 4-41a-104(5), the

- 405 department sets in accordance with Section 63J-1-504; and
- 406 (vi) a description of any investigation or adverse action taken by any licensing  
407 jurisdiction, government agency, law enforcement agency, or court in any state for  
408 any violation or detrimental conduct in relation to any of the applicant's  
409 cannabis-related operations or businesses.
- 410 (c)(i) A person may not locate a medical cannabis pharmacy:
- 411 (A) within 200 feet of a community location; or
- 412 (B) in or within 600 feet of a district that the relevant municipality or county has  
413 zoned as primarily residential.
- 414 (ii) The proximity requirements described in Subsection (2)(c)(i) shall be measured  
415 from the nearest entrance to the medical cannabis pharmacy establishment by  
416 following the shortest route of ordinary pedestrian travel to the property boundary  
417 of the community location or residential area.
- 418 (iii) The licensing board may grant a waiver to reduce the proximity requirements in  
419 Subsection (2)(c)(i) by up to 20% if the department determines that it is not  
420 reasonably feasible for the applicant to site the proposed medical cannabis  
421 pharmacy without the waiver.
- 422 (iv) An applicant for a license under this section shall provide evidence of  
423 compliance with the proximity requirements described in Subsection (2)(c)(i).
- 424 (d) The licensing board may not issue a license to an eligible applicant that the  
425 department has selected to receive a license until the selected eligible applicant  
426 complies with the bond or liquid cash requirement described in Subsection (2)(b)(iii).
- 427 (e) If the licensing board receives more than one application for a medical cannabis  
428 pharmacy within the same city or town, the department shall consult with the local  
429 land use authority before approving any of the applications pertaining to that city or  
430 town.
- 431 (f) In considering the issuance of a medical cannabis pharmacy license under this  
432 section, the licensing board may consider the extent to which the pharmacy can  
433 increase efficiency and reduce cost to patients of medical cannabis.
- 434 (3)(a) After an entity has been selected for a medical cannabis pharmacy license under  
435 this section, the department shall:
- 436 (i) charge the applicant an initial license fee in an amount that, subject to Subsection  
437 4-41a-104(5), the department sets in accordance with Section 63J-1-504;
- 438 (ii) notify the Department of Public Safety of the license approval and the names of

- 439 each individual described in Subsection (2)(b)(ii); and
- 440 (iii) charge the licensee a fee in an amount that, subject to Subsection 4-41a-104(5),
- 441 the department sets in accordance with Section 63J-1-504, for any change in
- 442 location, ownership, or company structure.
- 443 (b) For a fee described in Subsection (3)(a)(i), a license fee for a medical cannabis
- 444 pharmacy located in a medically underserved area as determined by the federal
- 445 Health Resources and Services Administration shall be 50% less than what is charged
- 446 for other medical cannabis pharmacies.
- 447 (4) The licensing board may not issue a license to operate a medical cannabis pharmacy to
- 448 an applicant if an individual described in Subsection (2)(b)(ii):
- 449 (a) has been convicted under state or federal law of:
- 450 (i) a felony in the preceding 10 years; or
- 451 (ii) after December 3, 2018, a misdemeanor for drug distribution;
- 452 (b) is younger than 21 years old; or
- 453 (c) after September 23, 2019, until January 1, 2023, is actively serving as a legislator.
- 454 (5) If an applicant for a medical cannabis pharmacy license under this section holds another
- 455 license under this chapter, the licensing board may not give preference to the applicant
- 456 based on the applicant's status as a holder of the license.
- 457 (6) The licensing board may revoke a license under this part:
- 458 (a) if the medical cannabis pharmacy does not begin operations within one year after the
- 459 day on which the department issues an announcement of the department's intent to
- 460 award a license to the medical cannabis pharmacy;
- 461 (b) after the third of the same violation of this chapter in any of the licensee's licensed
- 462 cannabis production establishments or medical cannabis pharmacies;
- 463 (c) if an individual described in Subsection (2)(b)(ii) is convicted, while the license is
- 464 active, under state or federal law of:
- 465 (i) a felony; or
- 466 (ii) after December 3, 2018, a misdemeanor for drug distribution;
- 467 (d) if the licensee fails to provide the information described in Subsection (2)(b)(vi) at
- 468 the time of application, or fails to supplement the information described in
- 469 Subsection (2)(b)(vi) with any investigation or adverse action that occurs after the
- 470 submission of the application within 14 calendar days after the licensee receives
- 471 notice of the investigation or adverse action;
- 472 (e) if the medical cannabis pharmacy demonstrates a willful or reckless disregard for the

- 473 requirements of this chapter or the rules the department makes in accordance with  
474 this chapter;
- 475 (f) if, after a change of ownership described in Subsection (10)(c), the department  
476 determines that the medical cannabis pharmacy no longer meets the minimum  
477 standards for licensure and operation of the medical cannabis pharmacy described in  
478 this chapter; or
- 479 (g) if through an investigation conducted under Subsection 4-41a-201.1(11) and in  
480 accordance with Title 63G, Chapter 4, Administrative Procedures Act, the licensing  
481 board finds that the licensee has participated in anticompetitive business practices.
- 482 (7)(a) A person who receives a medical cannabis pharmacy license under this chapter, if  
483 the municipality or county where the licensed medical cannabis pharmacy will be  
484 located requires a local land use permit, shall submit to the department a copy of the  
485 licensee's approved application for the land use permit within 120 days after the day  
486 on which the department issues the license.
- 487 (b) If a licensee fails to submit to the department a copy the licensee's approved land use  
488 permit application in accordance with Subsection (7)(a), the department may revoke  
489 the licensee's license.
- 490 (8) The department shall deposit the proceeds of a fee imposed by this section into the  
491 Qualified Production Enterprise Fund.
- 492 (9)(a) The licensing board's authority to issue a license under this section is plenary and  
493 is not subject to review.
- 494 (b) Notwithstanding Subsection (2), the decision of the department to award a license to  
495 an applicant is not subject to:
- 496 (i) Title 63G, Chapter 6a, Part 16, Protests; or  
497 (ii) Title 63G, Chapter 6a, Part 17, Procurement Appeals Board.
- 498 (10)(a) A medical cannabis pharmacy license is not transferrable or assignable.
- 499 (b) A medical cannabis pharmacy shall report in writing to the department no later than  
500 45 business days before the date of any change of ownership of the medical cannabis  
501 pharmacy.
- 502 (c) If the ownership of a medical cannabis pharmacy changes by 50% or more:
- 503 (i) concurrent with the report described in Subsection (10)(b), the medical cannabis  
504 pharmacy shall submit a new application described in Subsection (2)(b), subject to  
505 Subsection (2)(c);  
506 (ii) within [30] 60 days of the submission of the application, the licensing board shall:

- 507 (A) conduct an application review; and  
508 (B) award a license to the medical cannabis pharmacy for the remainder of the  
509 term of the medical cannabis pharmacy's license before the ownership change  
510 if the medical cannabis pharmacy meets the minimum standards for licensure  
511 and operation of the medical cannabis pharmacy described in this chapter; and  
512 (iii) if the department approves the license application, notwithstanding Subsection  
513 (3), the medical cannabis pharmacy shall pay a license fee that the department sets  
514 in accordance with Section 63J-1-504 in an amount that covers the department's  
515 cost of conducting the application review.

516 Section 5. Section **4-41a-1101** is amended to read:

517 **4-41a-1101 . Operating requirements -- General.**

- 518 (1)(a) A medical cannabis pharmacy shall operate:  
519 (i) at the physical address provided to the department under Section 4-41a-1001; and  
520 (ii) in accordance with the operating plan provided to the department under Section  
521 4-41a-1001 and, if applicable, Section 4-41a-1004.  
522 (b) A medical cannabis pharmacy shall notify the department before a change in the  
523 medical cannabis pharmacy's physical address or operating plan.  
524 (2) An individual may not enter a medical cannabis pharmacy unless the individual:  
525 (a) is at least 18 years old or is an emancipated minor under Section 80-7-105; and  
526 (b) except as provided in Subsection (4):  
527 (i) possesses a valid:  
528 (A) medical cannabis pharmacy agent registration card;  
529 (B) pharmacy medical provider registration card; or  
530 (C) medical cannabis card;  
531 (ii) is an employee of the department performing an inspection under Section  
532 4-41a-1103; or  
533 (iii) is another individual as the department provides.  
534 (3) A medical cannabis pharmacy may not employ an individual who is younger than 21  
535 years old.  
536 (4) Notwithstanding Subsection [(2)(a)] (2)(b), a medical cannabis pharmacy may authorize  
537 an individual who is not a medical cannabis pharmacy agent or pharmacy medical  
538 provider to access the medical cannabis pharmacy if the medical cannabis pharmacy  
539 tracks and monitors the individual at all times while the individual is at the medical  
540 cannabis pharmacy and maintains a record of the individual's access.

- 541 (5) A medical cannabis pharmacy shall operate in a facility that has:
- 542 (a) a single, secure public entrance;
- 543 (b) a security system with a backup power source that:
- 544 (i) detects and records entry into the medical cannabis pharmacy; and
- 545 (ii) provides notice of an unauthorized entry to law enforcement when the medical
- 546 cannabis pharmacy is closed; and
- 547 (c) a lock on each area where the medical cannabis pharmacy stores medical cannabis.
- 548 (6) A medical cannabis pharmacy shall post, both clearly and conspicuously in the medical
- 549 cannabis pharmacy, the limit on the purchase of cannabis described in Subsection
- 550 4-41a-1102(2).
- 551 (7) Except for an emergency situation described in Subsection 26B-4-213(3)(b), a medical
- 552 cannabis pharmacy may not allow any individual to consume cannabis on the property
- 553 or premises of the medical cannabis pharmacy.
- 554 (8) A medical cannabis pharmacy may not sell medical cannabis without first indicating on
- 555 the medical cannabis label the name of the medical cannabis pharmacy.
- 556 (9)(a) Each medical cannabis pharmacy shall retain in the pharmacy's records the
- 557 following information regarding each recommendation underlying a transaction:
- 558 (i) the recommending medical provider's name, address, and telephone number;
- 559 (ii) the patient's name and address;
- 560 (iii) the date of issuance;
- 561 (iv) directions of use and dosing guidelines or an indication that the recommending
- 562 medical provider did not recommend specific directions of use or dosing
- 563 guidelines; and
- 564 (v) if the patient did not complete the transaction, the name of the medical cannabis
- 565 cardholder who completed the transaction.
- 566 (b)(i) Except as provided in Subsection (9)(b)(iii), a medical cannabis pharmacy may
- 567 not sell medical cannabis unless the medical cannabis has a label securely affixed
- 568 to the container indicating the following minimum information:
- 569 (A) the name, address, and telephone number of the medical cannabis pharmacy;
- 570 (B) the unique identification number that the medical cannabis pharmacy assigns;
- 571 (C) the date of the sale;
- 572 (D) the name of the patient;
- 573 (E) the name of the recommending medical provider who recommended the
- 574 medical cannabis treatment;

- 575 (F) directions for use and cautionary statements, if any;  
576 (G) the amount dispensed and the cannabinoid content;  
577 (H) the suggested use date;  
578 (I) for unprocessed cannabis flower, the legal use termination date; and  
579 (J) any other requirements that the department determines, in consultation with the  
580 Division of Professional Licensing and the Board of Pharmacy.
- 581 (ii) A medical cannabis pharmacy is exempt from the requirement to provide the  
582 following information under Subsection (9)(b)(i) if the information is already  
583 provided on the product label that a cannabis production establishment affixes:  
584 (A) a unique identification number;  
585 (B) directions for use and cautionary statements;  
586 (C) amount and cannabinoid content; and  
587 (D) a suggested use date.
- 588 (iii) If the size of a medical cannabis container does not allow sufficient space to  
589 include the labeling requirements described in Subsection (9)(b)(i), the medical  
590 cannabis pharmacy may provide the following information described in  
591 Subsection (9)(b)(i) on a supplemental label attached to the container or an  
592 informational enclosure that accompanies the container:  
593 (A) the cannabinoid content;  
594 (B) the suggested use date; and  
595 (C) any other requirements that the department determines.
- 596 (iv) A medical cannabis pharmacy may sell medical cannabis to another medical  
597 cannabis pharmacy without a label described in Subsection (9)(b)(i).
- 598 (10) A pharmacy medical provider or medical cannabis pharmacy agent shall:  
599 (a) upon receipt of an order from a recommending medical provider in accordance with  
600 Subsections 26B-4-204(1)(b) and (c):  
601 (i) for a written order or an electronic order under circumstances that the department  
602 determines, contact the recommending medical provider or the recommending  
603 medical provider's office to verify the validity of the recommendation; and  
604 (ii) for an order that the pharmacy medical provider or medical cannabis pharmacy  
605 agent verifies under Subsection (10)(a)(i) or an electronic order that is not subject  
606 to verification under Subsection (10)(a)(i), enter the recommending medical  
607 provider's recommendation or renewal, including any associated directions of use,  
608 dosing guidelines, or caregiver indication, in the state electronic verification

- 609 system;
- 610 (b) in processing an order for a holder of a conditional medical cannabis card described  
611 in Subsection 26B-4-213(1)(b) that appears irregular or suspicious in the judgment of  
612 the pharmacy medical provider or medical cannabis pharmacy agent, contact the  
613 recommending medical provider or the recommending medical provider's office to  
614 verify the validity of the recommendation before processing the cardholder's order;
- 615 (c) unless the medical cannabis cardholder has had a consultation under Subsection  
616 26B-4-231(5), verbally offer to a medical cannabis cardholder at the time of a  
617 purchase of medical cannabis or a medical cannabis device, personal counseling with  
618 the pharmacy medical provider; and
- 619 (d) provide a telephone number or website by which the cardholder may contact a  
620 pharmacy medical provider for counseling.
- 621 (11)(a) A medical cannabis pharmacy may create a medical cannabis disposal program  
622 that allows an individual to deposit unused or excess medical cannabis or cannabis  
623 residue from a medical cannabis device in a locked box or other secure receptacle  
624 within the medical cannabis pharmacy.
- 625 (b) A medical cannabis pharmacy with a disposal program described in Subsection  
626 (11)(a) shall ensure that only a medical cannabis pharmacy agent or pharmacy  
627 medical provider can access deposited medical cannabis.
- 628 (c) A medical cannabis pharmacy shall dispose of any deposited medical cannabis by:  
629 (i) rendering the deposited medical cannabis unusable and unrecognizable before  
630 transporting deposited medical cannabis from the medical cannabis pharmacy; and  
631 (ii) disposing of the deposited medical cannabis in accordance with:  
632 (A) federal and state law, rules, and regulations related to hazardous waste;  
633 (B) the Resource Conservation and Recovery Act, 42 U.S.C. Sec. 6991 et seq.;  
634 (C) Title 19, Chapter 6, Part 5, Solid Waste Management Act; and  
635 (D) other regulations that the department makes in accordance with Title 63G,  
636 Chapter 3, Utah Administrative Rulemaking Act.
- 637 (12) A medical cannabis pharmacy:  
638 (a) shall employ a pharmacist who is licensed under Title 58, Chapter 17b, Pharmacy  
639 Practice Act, as a pharmacy medical provider;  
640 (b) may employ a physician who has the authority to write a prescription and is licensed  
641 under Title 58, Chapter 67, Utah Medical Practice Act, or Title 58, Chapter 68, Utah  
642 Osteopathic Medical Practice Act, as a pharmacy medical provider;

- 643 (c) shall ensure that a pharmacy medical provider described in Subsection (12)(a) works  
644 onsite during all business hours;
- 645 (d) shall designate one pharmacy medical provider described in Subsection (12)(a) as the  
646 pharmacist-in-charge to oversee the operation of and generally supervise the medical  
647 cannabis pharmacy;
- 648 (e) shall allow the pharmacist-in-charge to determine which medical cannabis products  
649 the medical cannabis pharmacy maintains in the medical cannabis pharmacy's  
650 inventory;
- 651 (f) for each medical cannabis product sold by the medical cannabis pharmacy, shall:  
652 (i) allow a medical cannabis cardholder located in the pharmacy to view the [~~back~~]  
653 fact panel of the product when requested; and  
654 (ii) beginning July 1, 2025, include a picture of the [~~back~~] fact panel of the product on  
655 the medical cannabis pharmacy's website;
- 656 (g) shall maintain a video surveillance system that:  
657 (i) tracks all handling of medical cannabis in the pharmacy;  
658 (ii) is tamper proof; and  
659 (iii) stores a video record for at least 45 days;
- 660 (h) shall provide the department access to the video surveillance system upon request;
- 661 (i) if a patient product information insert is available, shall provide a patient who  
662 purchases a medical cannabis product the medical cannabis product's patient product  
663 information insert using any of the following methods:  
664 (i) a physical document;  
665 (ii) an email message;  
666 (iii) a text message; or  
667 (iv) a quick response code; and
- 668 (j) may not allow a recommending medical provider to recommend medical cannabis as  
669 part of an event that:  
670 (i) is a temporary gathering, market, clinic, or promotional event;  
671 (ii) operates in a temporary tent or structure; and  
672 (iii) is held within 500 feet of the medical cannabis pharmacy's property line.
- 673 (13) The department shall establish by rule, in accordance with Title 63G, Chapter 3, Utah  
674 Administrative Rulemaking Act, protocols for a recall of cannabis and cannabis products  
675 by a medical cannabis pharmacy.

676 Section 6. Section **4-41a-1106** is amended to read:

677 **4-41a-1106 . Medical cannabis pharmacy agent -- Registration.**

- 678 (1) An individual may not serve as a medical cannabis pharmacy agent of a medical  
679 cannabis pharmacy unless the department registers the individual as a medical cannabis  
680 pharmacy agent.
- 681 (2) A recommending medical provider may not act as a medical cannabis pharmacy agent,  
682 have a financial or voting interest of 2% or greater in a medical cannabis pharmacy, or  
683 have the power to direct or cause the management or control of a medical cannabis  
684 pharmacy.
- 685 (3)(a) The department shall, within 15 days after the day on which the department  
686 receives a complete application from a medical cannabis pharmacy on behalf of a  
687 prospective medical cannabis pharmacy agent, register and issue a medical cannabis  
688 pharmacy agent registration card to the prospective agent if the medical cannabis  
689 pharmacy:
- 690 (i) provides to the department:
    - 691 (A) the prospective agent's name and address;
    - 692 (B) the name and location of the licensed medical cannabis pharmacy where the  
693 prospective agent seeks to act as the medical cannabis pharmacy agent; and
    - 694 (C) the submission required under Subsection (3)(b); and
  - 695 (ii) pays a fee to the department in an amount that, subject to Subsection 4-41a-104(5),  
696 the department sets in accordance with Section 63J-1-504.
- 697 (b) Each prospective agent described in Subsection (3)(a) shall:
- 698 (i) submit to the department:
    - 699 (A) a fingerprint card in a form acceptable to the Department of Public Safety; and
    - 700 (B) a signed waiver in accordance with Subsection 53-10-108(4) acknowledging  
701 the registration of the prospective agent's fingerprints in the Federal Bureau of  
702 Investigation Next Generation Identification System's Rap Back Service; and
  - 703 (ii) consent to a fingerprint background check by:
    - 704 (A) the Bureau of Criminal Identification; and
    - 705 (B) the Federal Bureau of Investigation.
- 706 (c) The Bureau of Criminal Identification shall:
- 707 (i) check the fingerprints the prospective agent submits under Subsection (3)(b)  
708 against the applicable state, regional, and national criminal records databases,  
709 including the Federal Bureau of Investigation Next Generation Identification  
710 System;

- 711 (ii) report the results of the background check to the department;
- 712 (iii) maintain a separate file of fingerprints that prospective agents submit under  
713 Subsection (3)(b) for search by future submissions to the local and regional  
714 criminal records databases, including latent prints;
- 715 (iv) request that the fingerprints be retained in the Federal Bureau of Investigation  
716 Next Generation Identification System's Rap Back Service for search by future  
717 submissions to national criminal records databases, including the Next Generation  
718 Identification System and latent prints; and
- 719 (v) establish a privacy risk mitigation strategy to ensure that the department only  
720 receives notifications for an individual with whom the department maintains an  
721 authorizing relationship.
- 722 (d) The department shall:
- 723 (i) assess an individual who submits fingerprints under Subsection (3)(b) a fee in an  
724 amount that the department sets in accordance with Section 63J-1-504 for the  
725 services that the Bureau of Criminal Identification or another authorized agency  
726 provides under this section; and
- 727 (ii) remit the fee described in Subsection (3)(d)(i) to the Bureau of Criminal  
728 Identification.
- 729 (4) A medical cannabis pharmacy agent shall comply with a certification standard that the  
730 department develops in collaboration with the Division of Professional Licensing and  
731 the Board of Pharmacy, or a third-party certification standard that the department  
732 designates by rule, in collaboration with the Division of Professional Licensing and the  
733 Board of Pharmacy and in accordance with Title 63G, Chapter 3, Utah Administrative  
734 Rulemaking Act.
- 735 (5) The department shall ensure that the certification standard described in Subsection (4)  
736 includes training in:
- 737 (a) Utah medical cannabis law; and  
738 (b) medical cannabis pharmacy best practices.
- 739 (6) The department [~~may~~] shall revoke the medical cannabis pharmacy agent registration  
740 card of, or refuse to issue a medical cannabis pharmacy agent registration card to, an  
741 individual who:
- 742 (a) violates the requirements of this chapter; or  
743 (b) is convicted under state or federal law of:  
744 (i) a felony within the preceding 10 years; or

- 745 (ii) after December 3, 2018, a misdemeanor for drug distribution.
- 746 (7)(a) A medical cannabis pharmacy agent registration card expires two years after the  
747 day on which the department issues or renews the card.
- 748 (b) A medical cannabis pharmacy agent may renew the agent's registration card if the  
749 agent:
- 750 (i) is eligible for a medical cannabis pharmacy agent registration card under this  
751 section;
- 752 (ii) certifies to the department in a renewal application that the information in  
753 Subsection (3)(a) is accurate or updates the information; and
- 754 (iii) pays to the department a renewal fee in an amount that:
- 755 (A) subject to Subsection 4-41a-104(5), the department sets in accordance with  
756 Section 63J-1-504; and
- 757 (B) may not exceed the cost of the relatively lower administrative burden of  
758 renewal in comparison to the original application process.
- 759 ~~[(8)(a) As a condition precedent to registration and renewal of a medical cannabis  
760 pharmacy agent registration card, a medical cannabis pharmacy agent shall:]~~
- 761 ~~[(i) complete at least one hour of continuing education regarding patient privacy and  
762 federal health information privacy laws that is offered by the department under  
763 Subsection (8)(b) or an accredited or approved continuing education provider that  
764 the department recognizes as offering continuing education appropriate for the  
765 medical cannabis pharmacy practice; and]~~
- 766 ~~[(ii) make a continuing education report to the department in accordance with a  
767 process that the department establishes by rule, in accordance with Title 63G,  
768 Chapter 3, Utah Administrative Rulemaking Act, and in collaboration with the  
769 Division of Professional Licensing and the Board of Pharmacy.]~~
- 770 ~~[(b) The department may, in consultation with the Division of Professional Licensing,  
771 develop the continuing education described in this Subsection (8).]~~
- 772 ~~[(c) The pharmacist in charge described in Section 26B-4-219 shall ensure that each  
773 medical cannabis pharmacy agent working in the medical cannabis pharmacy who  
774 has access to the state electronic verification system is in compliance with this  
775 Subsection (8).]~~
- 776 ~~[(d) A medical cannabis pharmacy agent may not access the electronic verification  
777 system following the termination of the medical cannabis pharmacy agent's  
778 employment.]~~

779 [(9)] (8) A medical cannabis pharmacy shall:

- 780 (a) maintain a list of employees that have a medical cannabis pharmacy agent  
781 registration card; and  
782 (b) provide the list to the department upon request.

783 Section 7. Section **4-41a-1201** is amended to read:

784 **4-41a-1201 . Medical cannabis home delivery designation.**

785 (1) The department may designate a medical cannabis pharmacy as a home delivery  
786 medical cannabis pharmacy if the department determines that the medical cannabis  
787 pharmacy's operating plan demonstrates the functional and technical ability to:

- 788 (a) safely conduct transactions for medical cannabis shipments; and  
789 (b) accept electronic medical cannabis orders[; ~~and~~] .

790 [(e) accept payments through:]

791 [(i) a payment provider that the Division of Finance approves, in consultation with  
792 the state treasurer, in accordance with Section 26-61a-603; or]

793 [(ii) a financial institution in accordance with Subsection 26-61a-603(4).]

794 (2) An applicant seeking a designation as a home delivery medical cannabis pharmacy shall  
795 identify in the applicant's operating plan any information relevant to the department's  
796 evaluation described in Subsection (1), including:

- 797 (a) the name and contact information of the payment provider;  
798 (b) the nature of the relationship between the prospective licensee and the payment  
799 provider;  
800 (c) the processes of the following to safely and reliably conduct transactions for medical  
801 cannabis shipments[;]

802 [(i) the prospective licensee; and

803 [(ii) the electronic payment provider or the financial institution described in  
804 Subsection (1)(e); and]

805 (d) the ability of the licensee to comply with the department's rules regarding the secure  
806 transportation and delivery of medical cannabis to a medical cannabis cardholder.

807 (3) Notwithstanding any county or municipal ordinance, a medical cannabis pharmacy that  
808 the department designates as a home delivery medical cannabis pharmacy may deliver  
809 medical cannabis shipments in accordance with this part.

810 Section 8. Section **4-41a-1204** is amended to read:

811 **4-41a-1204 . Medical cannabis courier agent -- Background check -- Registration**  
812 **card -- Rebuttable presumption.**

- 813 (1) An individual may not serve as a medical cannabis courier agent unless the department  
814 registers the individual as a medical cannabis courier agent.
- 815 (2)(a) The department shall, within 15 days after the day on which the department  
816 receives a complete application from a medical cannabis courier on behalf of a  
817 medical cannabis courier agent, register and issue a medical cannabis courier agent  
818 registration card to the prospective agent if the medical cannabis courier:
- 819 (i) provides to the department:
    - 820 (A) the prospective agent's name and address;
    - 821 (B) the name and address of the medical cannabis courier;
    - 822 (C) the name and address of each home delivery medical cannabis pharmacy with  
823 which the medical cannabis courier contracts to deliver medical cannabis  
824 shipments; and
    - 825 (D) the submission required under Subsection (2)(b);
  - 826 (ii) as reported under Subsection (2)(c), has not been convicted under state or federal  
827 law of:
    - 828 (A) a felony; or
    - 829 (B) after December 3, 2018, a misdemeanor for drug distribution; and
  - 830 (iii) pays the department a fee in an amount that, subject to Subsection 4-41a-104(5),  
831 the department sets in accordance with Section 63J-1-504.
- 832 (b) Each prospective agent described in Subsection (2)(a) shall:
- 833 (i) submit to the department:
    - 834 (A) a fingerprint card in a form acceptable to the Department of Public Safety; and
    - 835 (B) a signed waiver in accordance with Subsection 53-10-108(4) acknowledging  
836 the registration of the prospective agent's fingerprints in the Federal Bureau of  
837 Investigation Next Generation Identification System's Rap Back Service; and
  - 838 (ii) consent to a fingerprint background check by:
    - 839 (A) the Bureau of Criminal Identification; and
    - 840 (B) the Federal Bureau of Investigation.
- 841 (c) The Bureau of Criminal Identification shall:
- 842 (i) check the fingerprints the prospective agent submits under Subsection (2)(b)  
843 against the applicable state, regional, and national criminal records databases,  
844 including the Federal Bureau of Investigation Next Generation Identification  
845 System;
  - 846 (ii) report the results of the background check to the department;

- 847 (iii) maintain a separate file of fingerprints that prospective agents submit under  
848 Subsection (2)(b) for search by future submissions to the local and regional  
849 criminal records databases, including latent prints;
- 850 (iv) request that the fingerprints be retained in the Federal Bureau of Investigation  
851 Next Generation Identification System's Rap Back Service for search by future  
852 submissions to national criminal records databases, including the Next Generation  
853 Identification System and latent prints; and
- 854 (v) establish a privacy risk mitigation strategy to ensure that the department only  
855 receives notifications for an individual with whom the department maintains an  
856 authorizing relationship.
- 857 (d) The department shall:
- 858 (i) assess an individual who submits fingerprints under Subsection (2)(b) a fee in an  
859 amount that the department sets in accordance with Section 63J-1-504 for the  
860 services that the Bureau of Criminal Identification or another authorized agency  
861 provides under this section; and
- 862 (ii) remit the fee described in Subsection (2)(d)(i) to the Bureau of Criminal  
863 Identification.
- 864 (3)(a) A medical cannabis courier agent shall comply with a certification standard that  
865 the department develops, in collaboration with the Division of Professional Licensing  
866 and the Board of Pharmacy, or a third-party certification standard that the department  
867 designates by rule in collaboration with the Division of Professional Licensing and  
868 the Board of Pharmacy and in accordance with Title 63G, Chapter 3, Utah  
869 Administrative Rulemaking Act.
- 870 (b) The department shall ensure that the certification standard described in Subsection  
871 (3)(a) includes training in:
- 872 (i) Utah medical cannabis law;
- 873 (ii) the medical cannabis shipment process; and
- 874 (iii) medical cannabis courier agent best practices.
- 875 (4)(a) A medical cannabis courier agent registration card expires two years after the day  
876 on which the department issues or renews the card.
- 877 (b) A medical cannabis courier agent may renew the agent's registration card if the agent:
- 878 (i) is eligible for a medical cannabis courier agent registration card under this section;
- 879 (ii) certifies to the department in a renewal application that the information in  
880 Subsection (2)(a) is accurate or updates the information; and

- 881 (iii) pays to the department a renewal fee in an amount that:
- 882 (A) subject to Subsection 4-41a-104(5), the department sets in accordance with
- 883 Section 63J-1-504; and
- 884 (B) may not exceed the cost of the relatively lower administrative burden of
- 885 renewal in comparison to the original application process.
- 886 (5) The department [~~may~~] shall revoke or refuse to issue or renew the medical cannabis
- 887 courier agent registration card of an individual who:
- 888 (a) violates the requirements of this chapter; or
- 889 (b) is convicted under state or federal law of:
- 890 (i) a felony within the preceding 10 years; or
- 891 (ii) after December 3, 2018, a misdemeanor for drug distribution.
- 892 (6) A medical cannabis courier agent whom the department has registered under this section
- 893 shall carry the agent's medical cannabis courier agent registration card with the agent at
- 894 all times when:
- 895 (a) the agent is on the premises of the medical cannabis courier, a medical cannabis
- 896 pharmacy, or a delivery address; and
- 897 (b) the agent is handling a medical cannabis shipment.
- 898 (7) If a medical cannabis courier agent handling a medical cannabis shipment possesses the
- 899 shipment in compliance with Subsection (6):
- 900 (a) there is a rebuttable presumption that the agent possesses the shipment legally; and
- 901 (b) there is no probable cause, based solely on the agent's possession of the medical
- 902 cannabis shipment that the agent is engaging in illegal activity.
- 903 (8)(a) A medical cannabis courier agent who violates Subsection (6) is:
- 904 (i) guilty of an infraction; and
- 905 (ii) subject to a \$100 fine.
- 906 (b) An individual who is guilty of a violation described in Subsection (8)(a) is not guilty
- 907 of a violation of Title 58, Chapter 37, Utah Controlled Substances Act, for the
- 908 conduct underlying the violation described in Subsection (8)(a).
- 909 (9) A medical cannabis courier shall:
- 910 (a) maintain a list of employees who have a medical cannabis courier agent card; and
- 911 (b) provide the list to the department upon request.
- 912 Section 9. Section **4-41a-1205** is amended to read:
- 913 **4-41a-1205 . Home delivery of medical cannabis shipments.**
- 914 (1) An individual may not receive and a medical cannabis pharmacy agent or a medical

- 915 cannabis courier agent may not deliver a medical cannabis shipment from a home  
916 delivery medical cannabis pharmacy unless:
- 917 (a) the individual receiving the shipment presents:
- 918 (i) a government issued photo identification; and
- 919 (ii)(A) a valid medical cannabis card under the same name that appears on the  
920 government issued photo identification; or
- 921 (B) for a facility that a medical cannabis cardholder has designated as a caregiver  
922 under Subsection 26B-4-214(1)(b), evidence of the facility caregiver  
923 designation; and
- 924 (b) the delivery occurs at:
- 925 (i) the delivery address that is on file in the state electronic verification system; or
- 926 (ii) the facility that the medical cannabis cardholder has designated as a caregiver  
927 under Subsection 26B-4-214(1)(b).
- 928 (2)(a) A medical cannabis pharmacy agent may not deliver a medical cannabis shipment  
929 on behalf of a home delivery medical cannabis pharmacy unless the medical cannabis  
930 pharmacy agent is currently employed by the home delivery medical cannabis  
931 pharmacy.
- 932 (b) A medical cannabis courier agent may not deliver a medical cannabis shipment on  
933 behalf of a medical cannabis courier unless the medical cannabis courier agent is  
934 currently employed by the medical cannabis courier.
- 935 (c) Before a medical cannabis pharmacy agent or a medical cannabis courier agent  
936 distributes a medical cannabis shipment to a medical cannabis cardholder, the agent  
937 shall:
- 938 (i) verify the shipment information using the state electronic verification system;
- 939 (ii) ensure that the individual satisfies the identification requirements in Subsection  
940 (1);
- 941 (iii) verify that payment is complete; and
- 942 (iv) record the completion of the shipment transaction in a manner such that the  
943 delivery of the shipment will later be recorded within a reasonable period in the  
944 electronic verification system.
- 945 (3) [The] When delivering a medical cannabis shipment, a home delivery medical cannabis  
946 pharmacy or medical cannabis courier shall:
- 947 (a)~~(i)~~ store each medical cannabis shipment in a secure manner until the recipient  
948 medical cannabis cardholder receives the shipment or the medical cannabis

- 949 courier returns the shipment to the home delivery medical cannabis pharmacy in  
950 accordance with Subsection (4); ~~and~~
- 951 ~~[(ii)]~~ (b) use adequate storage or shipping containers and shipping processes to ensure  
952 medical cannabis stability and potency and appropriate storage temperatures  
953 throughout delivery;
- 954 (c) use shipping containers sealed in a manner to detect evidence of opening or  
955 tampering;
- 956 (d) ensure that only a home delivery medical cannabis pharmacy agent or medical  
957 cannabis courier agent is able to access the medical cannabis shipment until the  
958 recipient medical cannabis cardholder receives the shipment;
- 959 ~~[(b)]~~ (e) return any undelivered medical cannabis shipment to the home delivery medical  
960 cannabis pharmacy, in accordance with Subsection (4),~~[after the medical cannabis~~  
961 ~~courier has possessed the shipment for 10 business days]~~ within 14 days from the day  
962 the medical cannabis shipment was shipped; and
- 963 ~~[(e)]~~ (f) return any medical cannabis shipment to the home delivery medical cannabis  
964 pharmacy, in accordance with Subsection (4), if a medical cannabis cardholder  
965 refuses to accept the shipment.
- 966 (4)(a) If a medical cannabis courier or home delivery medical cannabis pharmacy agent  
967 returns an undelivered medical cannabis shipment ~~[that remains unopened, the home~~  
968 ~~delivery medical cannabis pharmacy may repackage or otherwise reuse the shipment]~~  
969 before the home delivery medical cannabis pharmacy may repackage the medical  
970 cannabis in the returned medical cannabis shipment, the pharmacist at the home  
971 delivery medical cannabis pharmacy shall:
- 972 (i) verify that the medical cannabis was returned to the original home delivery  
973 medical cannabis pharmacy within 14 days from the day the medical cannabis was  
974 shipped; and
- 975 (ii) determine in the pharmacist's clinical judgment that the medical cannabis's  
976 integrity is intact and the security of the drug packaging has not been compromised.
- 977 (b) ~~[If a medical cannabis courier or home delivery medical cannabis pharmacy agent~~  
978 ~~returns an undelivered or refused medical cannabis shipment under Subsection (3)~~  
979 ~~that appears to be opened in any way]~~ For returned medical cannabis described in  
980 Subsection (4)(a) that a pharmacist deems does not comply with Subsection (4)(a)(i)  
981 or (ii), the home delivery medical cannabis pharmacy shall dispose of the [shipment]  
982 medical cannabis by:

- 983 (i) rendering the [shipment] medical cannabis unusable and unrecognizable before  
984 transporting the [shipment] medical cannabis from the home delivery medical  
985 cannabis pharmacy; and
- 986 (ii) disposing of the [shipment] medical cannabis in accordance with:
- 987 (A) federal and state laws, rules, and regulations related to hazardous waste;
- 988 (B) the Resource Conservation and Recovery Act, 42 U.S.C. Sec. 6991 et seq.;
- 989 (C) Title 19, Chapter 6, Part 5, Solid Waste Management Act; and
- 990 (D) other regulations that the department makes in accordance with Title 63G,  
991 Chapter 3, Utah Administrative Rulemaking Act.

992 Section 10. Section **26B-1-421** is amended to read:

993 **26B-1-421 . Compassionate Use Board.**

994 (1) The definitions in Section 26B-4-201 apply to this section.

995 (2)(a) The department shall establish a Compassionate Use Board consisting of:

996 (i) seven [qualified] recommending medical providers that the executive director  
997 appoints with the advice and consent of the Senate:

998 (A) who are knowledgeable about the medicinal use of cannabis;

999 (B) who are physicians licensed under Title 58, Chapter 67, Utah Medical Practice  
1000 Act, or Title 58, Chapter 68, Utah Osteopathic Medical Practice Act; and

1001 (C) who are board certified by the American Board of Medical Specialties or an  
1002 American Osteopathic Association Specialty Certifying Board in the specialty  
1003 of neurology, pain medicine and pain management, medical oncology,  
1004 psychiatry, infectious disease, internal medicine, pediatrics, family medicine,  
1005 or gastroenterology; and

1006 (ii) as a nonvoting member and the chair of the Compassionate Use Board, the  
1007 executive director or the director's designee.

1008 (b) In appointing the seven [qualified] recommending medical providers described in  
1009 Subsection [~~(2)(a)~~] (2)(a)(i), the executive director shall ensure that at least two have a  
1010 board certification in pediatrics.

1011 (3)(a) Of the members of the Compassionate Use Board that the executive director first  
1012 appoints:

1013 (i) three shall serve an initial term of two years; and

1014 (ii) the remaining members shall serve an initial term of four years.

1015 (b) After an initial term described in Subsection (3)(a) expires:

1016 (i) each term is four years; and

- 1017 (ii) each board member is eligible for reappointment.
- 1018 (c) A member of the Compassionate Use Board may serve until a successor is appointed.
- 1019 (d) Four members constitute a quorum of the Compassionate Use Board.
- 1020 (4) A member of the Compassionate Use Board may receive:
- 1021 (a) notwithstanding Section 63A-3-106, compensation or benefits for the member's
- 1022 service; and
- 1023 (b) travel expenses in accordance with Section 63A-3-107 and rules made by the
- 1024 Division of Finance in accordance with Section 63A-3-107.
- 1025 (5) The Compassionate Use Board shall:
- 1026 (a) review and recommend for department approval a petition to the board regarding an
- 1027 individual described in Subsection 26B-4-213(2)(a), a minor described in Subsection
- 1028 26B-4-213(2)(c), or an individual who is not otherwise qualified to receive a medical
- 1029 cannabis card to obtain a medical cannabis card for compassionate use, for the
- 1030 standard or a reduced period of validity, if:
- 1031 (i) for an individual who is not otherwise qualified to receive a medical cannabis
- 1032 card, the individual's recommending medical provider is actively treating the
- 1033 individual for an intractable condition that:
- 1034 (A) substantially impairs the individual's quality of life; and
- 1035 (B) has not, in the recommending medical provider's professional opinion,
- 1036 adequately responded to conventional treatments;
- 1037 (ii) the recommending medical provider:
- 1038 (A) recommends that the individual or minor be allowed to use medical cannabis;
- 1039 and
- 1040 (B) provides a letter, relevant treatment history, and notes or copies of progress
- 1041 notes describing relevant treatment history including rationale for considering
- 1042 the use of medical cannabis; and
- 1043 (iii) the Compassionate Use Board determines that:
- 1044 (A) the recommendation of the individual's recommending medical provider is
- 1045 justified; and
- 1046 (B) based on available information, it may be in the best interests of the individual
- 1047 to allow the use of medical cannabis;
- 1048 (b) when a recommending medical provider recommends that an individual described in
- 1049 Subsection 26B-4-213(2)(a)(i)(B) or a minor described in Subsection 26B-4-213(2)(c)
- 1050 be allowed to use a medical cannabis device or medical cannabis to vaporize a

- 1051 medical cannabis treatment, review and approve or deny the use of the medical  
1052 cannabis device or medical cannabis;
- 1053 (c) unless no petitions are pending:
- 1054 (i) meet to receive or review compassionate use petitions at least quarterly; and  
1055 (ii) if there are more petitions than the board can receive or review during the board's  
1056 regular schedule, as often as necessary;
- 1057 (d) except as provided in Subsection (6), complete a review of each petition and  
1058 recommend to the department approval or denial of the applicant for qualification for  
1059 a medical cannabis card within 90 days after the day on which the board received the  
1060 petition; and
- 1061 (e) consult with the department regarding the criteria described in Subsection (6).
- 1062 (6) The department shall make rules, in consultation with the Compassionate Use Board  
1063 and in accordance with Title 63G, Chapter 3, Utah Administrative Rulemaking Act, to  
1064 establish a process and criteria for a petition to the board to automatically qualify for  
1065 expedited final review and approval or denial by the department in cases where, in the  
1066 determination of the department and the board:
- 1067 (a) time is of the essence;
- 1068 (b) engaging the full review process would be unreasonable in light of the petitioner's  
1069 physical condition; and
- 1070 (c) sufficient factors are present regarding the petitioner's safety.
- 1071 (7)(a)(i) The department shall review:
- 1072 (A) any compassionate use for which the Compassionate Use Board recommends  
1073 approval under Subsection (5)(d) to determine whether the board properly  
1074 exercised the board's discretion under this section; and
- 1075 (B) any expedited petitions the department receives under the process described in  
1076 Subsection (6).
- 1077 (ii) If the department determines that the Compassionate Use Board properly  
1078 exercised the board's discretion in recommending approval under Subsection (5)(d)  
1079 or that the expedited petition merits approval based on the criteria established in  
1080 accordance with Subsection (6), the department shall:
- 1081 (A) issue the relevant medical cannabis card; and  
1082 (B) provide for the renewal of the medical cannabis card in accordance with the  
1083 recommendation of the recommending medical provider described in  
1084 Subsection (5)(a).

- 1085 (b) If the Compassionate Use Board recommends denial under Subsection (5)(d), the  
 1086 individual seeking to obtain a medical cannabis card may petition the department to  
 1087 review the board's decision.
- 1088 (c) In reviewing the Compassionate Use Board's recommendation for approval or denial  
 1089 under Subsection (5)(d) in accordance with this Subsection (7), the department shall  
 1090 presume the board properly exercised the board's discretion unless the department  
 1091 determines that the board's recommendation was arbitrary or capricious.
- 1092 (8) Any individually identifiable health information contained in a petition that the  
 1093 Compassionate Use Board or department receives under this section is a protected  
 1094 record in accordance with Title 63G, Chapter 2, Government Records Access and  
 1095 Management Act.
- 1096 (9) The Compassionate Use Board shall annually report the board's activity to the advisory  
 1097 board.

1098 Section 11. Section **26B-4-201** is amended to read:

1099 **26B-4-201 . Definitions.**

1100 As used in this part:

- 1101 (1) "Active tetrahydrocannabinol" means THC, any THC analog, and  
 1102 tetrahydrocannabinolic acid.
- 1103 (2) "Administration of criminal justice" means the performance of detection, apprehension,  
 1104 detention, pretrial release, post-trial release, prosecution, and adjudication.
- 1105 (3) "Advertise" means information provided by a person in any medium:  
 1106 (a) to the public; and  
 1107 (b) that is not age restricted to an individual who is at least 21 years old.
- 1108 (4) "Advisory board" means the Medical Cannabis Policy Advisory Board created in  
 1109 Section 26B-1-435.
- 1110 (5) "Cannabis" means marijuana.
- 1111 (6) "Cannabis processing facility" means the same as that term is defined in Section  
 1112 4-41a-102.
- 1113 (7) "Cannabis product" means a product that:  
 1114 (a) is intended for human use; and  
 1115 (b) contains cannabis or any tetrahydrocannabinol or THC analog in a total  
 1116 concentration of 0.3% or greater on a dry weight basis.
- 1117 (8) "Cannabis production establishment" means the same as that term is defined in Section  
 1118 4-41a-102.

- 1119 (9) "Cannabis production establishment agent" means the same as that term is defined in  
1120 Section 4-41a-102.
- 1121 (10) "Cannabis production establishment agent registration card" means the same as that  
1122 term is defined in Section 4-41a-102.
- 1123 (11) "Conditional medical cannabis card" means an electronic medical cannabis card that  
1124 the department issues in accordance with Subsection 26B-4-213(1)(b) to allow an  
1125 applicant for a medical cannabis card to access medical cannabis during the department's  
1126 review of the application.
- 1127 (12) "Controlled substance database" means the controlled substance database created in  
1128 Section 58-37f-201.
- 1129 (13) "Delivery address" means the same as that term is defined in Section 4-41a-102.
- 1130 (14) "Department" means the Department of Health and Human Services.
- 1131 (15) "Designated caregiver" means:
- 1132 (a) an individual:
- 1133 (i) whom an individual with a medical cannabis patient card or a medical cannabis  
1134 guardian card designates as the patient's caregiver; and
- 1135 (ii) who registers with the department under Section 26B-4-214; or
- 1136 (b)(i) a facility that an individual designates as a designated caregiver in accordance  
1137 with Subsection 26B-4-214(1)(b); or
- 1138 (ii) an assigned employee of the facility described in Subsection 26B-4-214(1)(b)(ii).
- 1139 (16) "Directions of use" means recommended routes of administration for a medical  
1140 cannabis treatment and suggested usage guidelines.
- 1141 (17) "Dosing guidelines" means a quantity range and frequency of administration for a  
1142 recommended treatment of medical cannabis.
- 1143 (18) "Government issued photo identification" means any of the following forms of  
1144 identification:
- 1145 (a) a valid state-issued driver license or identification card;
- 1146 (b) a valid United States federal-issued photo identification, including:
- 1147 (i) a United States passport;
- 1148 (ii) a United States passport card;
- 1149 (iii) a United States military identification card; or
- 1150 (iv) a permanent resident card or alien registration receipt card; [Ø]
- 1151 (c) a foreign passport[-] ; or
- 1152 (d) a tribal government-issued photo identification.

- 1153 (19) "Home delivery medical cannabis pharmacy" means a medical cannabis pharmacy that  
1154 the department authorizes, as part of the pharmacy's license, to deliver medical cannabis  
1155 shipments to a delivery address to fulfill electronic orders.
- 1156 (20) "Incapacitated" means the same as that term is defined in Section 75-1-201.
- 1157 [~~(20)~~] (21) "Inventory control system" means the system described in Section 4-41a-103.
- 1158 [~~(21)~~] (22) "Legal dosage limit" means an amount that:
- 1159 (a) is sufficient to provide 30 days of treatment based on the dosing guidelines that the  
1160 relevant recommending medical provider or pharmacy medical provider, in  
1161 accordance with Subsection 26B-4-231(5), recommends; and
- 1162 (b) may not exceed:
- 1163 (i) for unprocessed cannabis in a medicinal dosage form, 113 grams by weight; and  
1164 (ii) for a cannabis product in a medicinal dosage form, a quantity that contains, in  
1165 total, greater than 20 grams of active tetrahydrocannabinol.
- 1166 [~~(22)~~] (23) "Legal use termination date" means a date on the label of a container of  
1167 unprocessed cannabis flower:
- 1168 (a) that is 60 days after the date of purchase of the cannabis; and  
1169 (b) after which, the cannabis is no longer in a medicinal dosage form outside of the  
1170 primary residence of the relevant medical cannabis patient cardholder.
- 1171 [~~(23)~~] (24) "Marijuana" means the same as that term is defined in Section 58-37-2.
- 1172 [~~(24)~~] (25) "Medical cannabis" or "medical cannabis product" means cannabis in a  
1173 medicinal dosage form or a cannabis product in a medicinal dosage form.
- 1174 [~~(25)~~] (26) "Medical cannabis card" means a medical cannabis patient card, a medical  
1175 cannabis guardian card, a medical cannabis caregiver card, or a conditional medical  
1176 cannabis card.
- 1177 [~~(26)~~] (27) "Medical cannabis cardholder" means:
- 1178 (a) a holder of a medical cannabis card; or  
1179 (b) a facility or assigned employee, described in Subsection (15)(b), only:
- 1180 (i) within the scope of the facility's or assigned employee's performance of the role of  
1181 a medical cannabis patient cardholder's caregiver designation under Subsection  
1182 26B-4-214(1)(b); and
- 1183 (ii) while in possession of documentation that establishes:
- 1184 (A) a caregiver designation described in Subsection 26B-4-214(1)(b);  
1185 (B) the identity of the individual presenting the documentation; and  
1186 (C) the relation of the individual presenting the documentation to the caregiver

- 1187 designation.
- 1188 [(27)] (28) "Medical cannabis caregiver card" means an electronic document that a  
1189 cardholder may print or store on an electronic device or a physical card or document that:  
1190 (a) the department issues to an individual whom a medical cannabis patient cardholder  
1191 or a medical cannabis guardian cardholder designates as a designated caregiver; and  
1192 (b) is connected to the electronic verification system.
- 1193 [(28)] (29) "Medical cannabis courier" means the same as that term is defined in Section  
1194 4-41a-102.
- 1195 [(29)] (30)(a) "Medical cannabis device" means a device that an individual uses to ingest  
1196 or inhale medical cannabis.  
1197 (b) "Medical cannabis device" does not include a device that:  
1198 (i) facilitates cannabis combustion; or  
1199 (ii) an individual uses to ingest substances other than cannabis.
- 1200 [(30)] (31) "Medical cannabis guardian card" means an electronic document that a  
1201 cardholder may print or store on an electronic device or a physical card or document that:  
1202 (a) the department issues to the parent or legal guardian of a minor [~~with a qualifying~~  
1203 ~~condition~~] or legal guardian of an incapacitated adult; and  
1204 (b) is connected to the electronic verification system.
- 1205 [(31)] (32) "Medical cannabis patient card" means an electronic document that a cardholder  
1206 may print or store on an electronic device or a physical card or document that:  
1207 (a) the department issues to an individual with a qualifying condition; and  
1208 (b) is connected to the electronic verification system.
- 1209 [(32)] (33) "Medical cannabis pharmacy" means a person that:  
1210 (a)(i) acquires or intends to acquire medical cannabis from a cannabis processing  
1211 facility or another medical cannabis pharmacy or a medical cannabis device; or  
1212 (ii) possesses medical cannabis or a medical cannabis device; and  
1213 (b) sells or intends to sell medical cannabis or a medical cannabis device to a medical  
1214 cannabis cardholder.
- 1215 [(33)] (34) "Medical cannabis pharmacy agent" means an individual who holds a valid  
1216 medical cannabis pharmacy agent registration card issued by the department.
- 1217 [(34)] (35) "Medical cannabis pharmacy agent registration card" means a registration card  
1218 issued by the department that authorizes an individual to act as a medical cannabis  
1219 pharmacy agent.
- 1220 [(35)] (36) "Medical cannabis shipment" means the same as that term is defined in Section

1221 4-41a-102.

1222 [(36)] (37) "Medical cannabis treatment" means medical cannabis or a medical cannabis  
1223 device.

1224 [(37)] (38)(a) "Medicinal dosage form" means:

1225 (i) for processed medical cannabis, the following with a specific and consistent  
1226 cannabinoid content:

1227 (A) a tablet;

1228 (B) a capsule;

1229 (C) a concentrated liquid or viscous oil;

1230 (D) a liquid suspension that does not exceed 30 milliliters;

1231 (E) a topical preparation;

1232 (F) a transdermal preparation;

1233 (G) a sublingual preparation;

1234 (H) a gelatinous cube, gelatinous rectangular cuboid, or lozenge in a cube or  
1235 rectangular cuboid shape;

1236 (I) a resin or wax;

1237 (J) an aerosol;

1238 (K) a suppository preparation; or

1239 (L) a soft or hard confection that is a uniform rectangular cuboid or uniform  
1240 spherical shape, is homogeneous in color and texture, and each piece is a single  
1241 serving; or

1242 (ii) for unprocessed cannabis flower, a container described in Section 4-41a-602 that:

1243 (A) contains cannabis flower in a quantity that varies by no more than 10% from  
1244 the stated weight at the time of packaging;

1245 (B) at any time the medical cannabis cardholder transports or possesses the  
1246 container in public, is contained within an opaque bag or box that the medical  
1247 cannabis pharmacy provides; and

1248 (C) is labeled with the container's content and weight, the date of purchase, the  
1249 legal use termination date, and a barcode that provides information connected  
1250 to an inventory control system.

1251 (b) "Medicinal dosage form" includes a portion of unprocessed cannabis flower that:

1252 (i) the medical cannabis cardholder has recently removed from the container  
1253 described in Subsection [(37)(a)(ii)] (38)(a)(ii) for use; and

1254 (ii) does not exceed the quantity described in Subsection [(37)(a)(ii)] (38)(a)(ii).

- 1255 (c) "Medicinal dosage form" does not include:
- 1256 (i) any unprocessed cannabis flower outside of the container described in Subsection [  
1257 ~~(37)(a)(ii)~~ (38)(a)(ii), except as provided in Subsection [~~(37)(b)~~ (38)(b)];
- 1258 (ii) any unprocessed cannabis flower in a container described in Subsection [  
1259 ~~(37)(a)(ii)~~ (38)(a)(ii) after the legal use termination date;
- 1260 (iii) a process of vaporizing and inhaling concentrated cannabis by placing the  
1261 cannabis on a nail or other metal object that is heated by a flame, including a  
1262 blowtorch;
- 1263 (iv) a liquid suspension that is branded as a beverage;
- 1264 (v) a substance described in Subsection [~~(37)(a)(i)~~ (38)(a)(i) or (ii) if the substance is  
1265 not measured in grams, milligrams, or milliliters; or
- 1266 (vi) a substance that contains or is covered to any degree with chocolate.
- 1267 [~~(38)~~ (39)] "Nonresident patient" means an individual who:
- 1268 (a) is not a resident of Utah or has been a resident of Utah for less than 45 days;
- 1269 (b) has a currently valid medical cannabis card or the equivalent of a medical cannabis  
1270 card under the laws of another state, district, territory, commonwealth, or insular  
1271 possession of the United States; and
- 1272 (c) has been diagnosed with a qualifying condition as described in Section 26B-4-203.
- 1273 [~~(39)~~ (40)] "Patient product information insert" means a single page document or webpage  
1274 that contains information about a medical cannabis product regarding:
- 1275 (a) how to use the product;
- 1276 (b) common side effects;
- 1277 (c) serious side effects;
- 1278 (d) dosage;
- 1279 (e) contraindications;
- 1280 (f) safe storage;
- 1281 (g) information on when a product should not be used; and
- 1282 (h) other information the department deems appropriate in consultation with the  
1283 cannabis processing facility that created the product.
- 1284 [~~(40)~~ (41)] "Pharmacy medical provider" means the medical provider required to be on site  
1285 at a medical cannabis pharmacy under Section 26B-4-219.
- 1286 [~~(41)~~ (42)] "Provisional patient card" means a card that:
- 1287 (a) the department issues to a minor [~~with a qualifying condition~~] or incapacitated adult  
1288 for whom:

- 1289 (i) a recommending medical provider has recommended a medical cannabis  
 1290 treatment; and
- 1291 (ii) the department issues a medical cannabis guardian card to the minor's parent or  
 1292 legal guardian or the incapacitated adult's legal guardian; and
- 1293 (b) is connected to the electronic verification system.
- 1294 [~~(42)~~] (43) "Qualified Patient Enterprise Fund" means the enterprise fund created in Section  
 1295 26B-1-310.
- 1296 [~~(43)~~] (44) "Qualifying condition" means a condition described in Section 26B-4-203.
- 1297 [~~(44)~~] (45) "Recommend" or "recommendation" means, for a recommending medical  
 1298 provider, the act of suggesting the use of medical cannabis treatment, which:
- 1299 (a) certifies the patient's eligibility for a medical cannabis card; and
- 1300 (b) may include, at the recommending medical provider's discretion, directions of use,  
 1301 with or without dosing guidelines.
- 1302 [~~(45)~~] (46) "Recommending medical provider" means an individual who:
- 1303 (a) meets the recommending qualifications;
- 1304 (b) completes four hours of continuing medical education specific to medical cannabis  
 1305 through formal or informal sources; and
- 1306 (c) every two years, provides an acknowledgment to the department that the individual  
 1307 completed four hours of continuing medical education.
- 1308 [~~(46)~~] (47) "Recommending qualifications" means that an individual:
- 1309 (a)(i) has the authority to write a prescription;
- 1310 (ii) is licensed to prescribe a controlled substance under Title 58, Chapter 37, Utah  
 1311 Controlled Substances Act; and
- 1312 (iii) possesses the authority, in accordance with the individual's scope of practice, to  
 1313 prescribe a Schedule II controlled substance; and
- 1314 (b) is licensed as:
- 1315 (i) a podiatrist under Title 58, Chapter 5a, Podiatric Physician Licensing Act;
- 1316 (ii) an advanced practice registered nurse under Title 58, Chapter 31b, Nurse Practice  
 1317 Act;
- 1318 (iii) a physician under Title 58, Chapter 67, Utah Medical Practice Act, or Title 58,  
 1319 Chapter 68, Utah Osteopathic Medical Practice Act; or
- 1320 (iv) a physician assistant under Title 58, Chapter 70a, Utah Physician Assistant Act.
- 1321 [~~(47)~~] (48) "State electronic verification system" means the system described in Section  
 1322 26B-4-202.

1323 [(48)] (49) "Targeted marketing" means the promotion by a recommending medical  
1324 provider, medical clinic, or medical office that employs a recommending medical  
1325 provider of a medical cannabis recommendation service using any of the following  
1326 methods:

- 1327 (a) electronic communication to an individual who is at least 21 years old and has  
1328 requested to receive promotional information;
- 1329 (b) an in-person marketing event that is held in an area where only an individual who is  
1330 at least 21 years old may access the event;
- 1331 (c) other marketing material that is physically or digitally displayed in the office of the  
1332 medical clinic or office that employs a recommending medical provider; or
- 1333 (d) a leaflet that a recommending medical provider, medical clinic, or medical office that  
1334 employs a recommending medical provider shares with an individual who is at least  
1335 21 years old.

1336 [(49)] (50) "Tetrahydrocannabinol" or "THC" means a substance derived from cannabis or a  
1337 synthetic equivalent as described in Subsection 58-37-4(2)(a)(iii)(AA).

1338 [(50)] (51) "THC analog" means the same as that term is defined in Section 4-41-102.

1339 Section 12. Section **26B-4-202** is amended to read:

1340 **26B-4-202 . Electronic verification system.**

- 1341 (1) The Department of Agriculture and Food, the department, the Department of Public  
1342 Safety, and the Division of Technology Services shall:
  - 1343 (a) enter into a memorandum of understanding in order to determine the function and  
1344 operation of the state electronic verification system in accordance with Subsection (2);
  - 1345 (b) coordinate with the Division of Purchasing and General Services, under Title 63G,  
1346 Chapter 6a, Utah Procurement Code, to develop a request for proposals for a  
1347 third-party provider to develop and maintain the state electronic verification system  
1348 in coordination with the Division of Technology Services; and
  - 1349 (c) select a third-party provider who:
    - 1350 (i) meets the requirements contained in the request for proposals issued under  
1351 Subsection (1)(b); and
    - 1352 (ii) may not have any commercial or ownership interest in a cannabis production  
1353 establishment or a medical cannabis pharmacy.
- 1354 (2) The Department of Agriculture and Food, the department, the Department of Public  
1355 Safety, and the Division of Technology Services shall ensure that the state electronic  
1356 verification system described in Subsection (1):

- 1357 (a) allows an individual to apply for a medical cannabis patient card or, if applicable, a  
1358 medical cannabis guardian card, provided that the card may not become active until:  
1359 (i) the relevant recommending medical provider completes the associated medical  
1360 cannabis recommendation; or  
1361 (ii) the medical cannabis pharmacy completes the recording described in [~~Subsection~~  
1362 ~~(2)(d)~~] Subsections (2)(d)(ii) and (iii);
- 1363 (b) allows an individual to apply to renew a medical cannabis patient card or a medical  
1364 cannabis guardian card in accordance with Section 26B-4-213;
- 1365 (c) allows a recommending medical provider, or an employee described in Subsection (3)  
1366 acting on behalf of the recommending medical provider, to:
- 1367 (i) access dispensing and card status information regarding a patient:  
1368 (A) with whom the recommending medical provider has a provider-patient  
1369 relationship; and  
1370 (B) for whom the recommending medical provider has recommended or is  
1371 considering recommending a medical cannabis card;
- 1372 (ii) electronically recommend treatment with medical cannabis and optionally  
1373 recommend dosing guidelines;
- 1374 (iii) electronically renew a recommendation to a medical cannabis patient cardholder  
1375 or medical cannabis guardian cardholder:  
1376 (A) using telehealth services, for the recommending medical provider who  
1377 originally recommended a medical cannabis treatment during a face-to-face  
1378 visit with the patient; or  
1379 (B) during a face-to-face visit with the patient, for a recommending medical  
1380 provider who did not originally recommend the medical cannabis treatment  
1381 during a face-to-face visit; and
- 1382 (iv) submit an initial application, renewal application, or application payment on  
1383 behalf of an individual applying for any of the following:  
1384 (A) a medical cannabis patient card;  
1385 (B) a medical cannabis guardian card; or  
1386 (C) a medical cannabis caregiver card;
- 1387 (d) allows a medical cannabis pharmacy medical provider or medical cannabis pharmacy  
1388 agent, in accordance with Subsection 4-41a-1101(10)(a), to:  
1389 (i) access the electronic verification system to review the history within the system of  
1390 a patient with whom the provider or agent is interacting, limited to read-only

- 1391 access for medical cannabis pharmacy agents unless the medical cannabis  
1392 pharmacy's pharmacist in charge authorizes add and edit access;
- 1393 (ii) record a patient's recommendation from a recommending medical provider,  
1394 including any directions of use, dosing guidelines, or caregiver indications from  
1395 the recommending medical provider;
- 1396 (iii) record a recommending medical provider's renewal of the provider's previous  
1397 recommendation; and
- 1398 (iv) submit an initial application, renewal application, or application payment on  
1399 behalf of an individual applying for any of the following:
- 1400 (A) a medical cannabis patient card;  
1401 (B) a medical cannabis guardian card; or  
1402 (C) a medical cannabis caregiver card;
- 1403 (e) connects with:
- 1404 (i) an inventory control system that a medical cannabis pharmacy uses to track in real  
1405 time and archive purchases of any medical cannabis or a medical cannabis device,  
1406 including:
- 1407 (A) the time and date of each purchase;  
1408 (B) the quantity and type of medical cannabis or medical cannabis device  
1409 purchased;  
1410 (C) any cannabis production establishment, any medical cannabis pharmacy, or  
1411 any medical cannabis courier associated with the medical cannabis or medical  
1412 cannabis device; and  
1413 (D) the personally identifiable information of the medical cannabis cardholder  
1414 who made the purchase; and
- 1415 (ii) any commercially available inventory control system that a cannabis production  
1416 establishment utilizes in accordance with Section 4-41a-103 to use data that the  
1417 Department of Agriculture and Food requires by rule, in accordance with Title  
1418 63G, Chapter 3, Utah Administrative Rulemaking Act, from the inventory  
1419 tracking system that a licensee uses to track and confirm compliance;
- 1420 (f) provides access to:
- 1421 (i) the department to the extent necessary to carry out the department's functions and  
1422 responsibilities under this part;
- 1423 (ii) the Department of Agriculture and Food to the extent necessary to carry out the  
1424 functions and responsibilities of the Department of Agriculture and Food under

- 1425 Title 4, Chapter 41a, Cannabis Production Establishments and Pharmacies; and  
1426 (iii) the Division of Professional Licensing to the extent necessary to carry out the  
1427 functions and responsibilities related to the participation of the following in the  
1428 recommendation and dispensing of medical cannabis:
- 1429 (A) a podiatrist licensed under Title 58, Chapter 5a, Podiatric Physician Licensing  
1430 Act;
  - 1431 (B) a pharmacist licensed under Title 58, Chapter 17b, Pharmacy Practice Act;
  - 1432 (C) an advanced practice registered nurse licensed under Title 58, Chapter 31b,  
1433 Nurse Practice Act;
  - 1434 (D) a physician licensed under Title 58, Chapter 67, Utah Medical Practice Act, or  
1435 Title 58, Chapter 68, Utah Osteopathic Medical Practice Act; or
  - 1436 (E) a physician assistant licensed under Title 58, Chapter 70a, Utah Physician  
1437 Assistant Act;
- 1438 (g) communicates dispensing information from a record that a medical cannabis  
1439 pharmacy submits to the state electronic verification system under Subsection  
1440 4-41a-1102(3)(a)(ii) to the controlled substance database;
- 1441 (h) provides access to state or local law enforcement only to verify the validity of an  
1442 individual's medical cannabis card for the administration of criminal justice and  
1443 through a database used by law enforcement; and
- 1444 (i) creates a record each time a person accesses the system that identifies the person who  
1445 accesses the system and the individual whose records the person accesses.
- 1446 (3)(a) An employee of a recommending medical provider may access the electronic  
1447 verification system for a purpose described in Subsection (2)(c) on behalf of the  
1448 recommending medical provider if:
- 1449 (i) the recommending medical provider has designated the employee as an individual  
1450 authorized to access the electronic verification system on behalf of the  
1451 recommending medical provider;
  - 1452 (ii) the recommending medical provider provides written notice to the department of  
1453 the employee's identity and the designation described in Subsection (3)(a)(i); and
  - 1454 (iii) the department grants to the employee access to the electronic verification  
1455 system.
- 1456 (b) An employee of a business that employs a recommending medical provider may  
1457 access the electronic verification system for a purpose described in Subsection (2)(c)  
1458 on behalf of the recommending medical provider if:

- 1459 (i) the recommending medical provider has designated the employee as an individual  
1460 authorized to access the electronic verification system on behalf of the  
1461 recommending medical provider;
- 1462 (ii) the recommending medical provider and the employing business jointly provide  
1463 written notice to the department of the employee's identity and the designation  
1464 described in Subsection (3)(b)(i); and
- 1465 (iii) the department grants to the employee access to the electronic verification  
1466 system.
- 1467 (c) Every two years, an employee described in Subsections (3)(a) and (3)(b) shall  
1468 complete at least one hour of education regarding health information privacy laws  
1469 that is offered by the department or an accredited or approved education provider that  
1470 the department recognizes before the department may grant the employee access to  
1471 the electronic verification system.

1472 (4)(a) Subject to Subsection (4)(c), a medical cannabis pharmacy agent may access the  
1473 electronic verification system for a purpose described in Subsection (2)(d) if:

1474 (i) the pharmacist-in-charge has designated the agent as an individual authorized to  
1475 access the electronic verification system;

1476 (ii) the agent completes continuing education regarding health information privacy  
1477 laws that is offered by the department or an accredited or approved education  
1478 provider that the department recognizes;

1479 (iii) the agent has completed the training described in Subsection (4)(a)(ii) within the  
1480 previous two years; and

1481 (iv) the department grants to the agent access to the electronic verification system.

1482 (b) The pharmacist-in-charge shall ensure that each medical cannabis pharmacy agent  
1483 working in the medical cannabis pharmacy who has access to the state electronic  
1484 verification system is in compliance with Subsection (4)(a).

1485 (c) A medical cannabis pharmacy agent may not access the electronic verification  
1486 system if the medical cannabis agent is not employed by a medical cannabis  
1487 pharmacy.

1488 [(4)] (5)(a) As used in this Subsection [(4)] (5), "prescribing provider" means:

1489 (i) a podiatrist licensed under Title 58, Chapter 5a, Podiatric Physician Licensing Act;

1490 (ii) an advanced practice registered nurse licensed under Title 58, Chapter 31b, Nurse  
1491 Practice Act;

1492 (iii) a physician licensed under Title 58, Chapter 67, Utah Medical Practice Act, or

- 1493 Title 58, Chapter 68, Utah Osteopathic Medical Practice Act; or  
 1494 (iv) a physician assistant licensed under Title 58, Chapter 70a, Utah Physician  
 1495 Assistant Act.
- 1496 (b) A prescribing provider may access information in the electronic verification system  
 1497 regarding a patient the prescribing provider treats.
- 1498 ~~[(5)]~~ (6) The department may release limited data that the system collects for the purpose of:  
 1499 (a) conducting medical and other department approved research;  
 1500 (b) providing the report required by Section 26B-4-222; and  
 1501 (c) other official department purposes.
- 1502 ~~[(6)]~~ (7) The department shall make rules, in accordance with Title 63G, Chapter 3, Utah  
 1503 Administrative Rulemaking Act, to establish:  
 1504 (a) the limitations on access to the data in the state electronic verification system as  
 1505 described in this section; and  
 1506 (b) standards and procedures to ensure accurate identification of an individual requesting  
 1507 information or receiving information in this section.
- 1508 ~~[(7)]~~ (8) Any person who negligently or recklessly releases any information in the state  
 1509 electronic verification system in violation of this section is guilty of a class C  
 1510 misdemeanor.
- 1511 ~~[(8)]~~ (9) Any person who obtains or attempts to obtain information from the state electronic  
 1512 verification system by misrepresentation or fraud is guilty of a third degree felony.
- 1513 ~~[(9)]~~ (10)(a) Except as provided in ~~[Subsections (9)(e) and]~~ Subsection (9)(e) and  
 1514 Subsection (11), a person may not knowingly and intentionally use, release, publish,  
 1515 or otherwise make available to any other person information obtained from the state  
 1516 electronic verification system for any purpose other than a purpose specified in this  
 1517 section.
- 1518 (b) Each separate violation of ~~[this]~~ Subsection ~~[(9)]~~ (10) is:  
 1519 (i) a third degree felony; and  
 1520 (ii) subject to a civil penalty not to exceed \$5,000.
- 1521 ~~[(e) A law enforcement officer who uses the database used by law enforcement to access~~  
 1522 ~~information in the electronic verification system for a reason that is not the~~  
 1523 ~~administration of criminal justice is guilty of a class B misdemeanor.]~~
- 1524 ~~[(d)]~~ (c) The department shall determine a civil violation of this Subsection ~~[(9)]~~ (10) in  
 1525 accordance with Title 63G, Chapter 4, Administrative Procedures Act.
- 1526 ~~[(e)]~~ (d) Civil penalties assessed under this Subsection ~~[(9)]~~ (10) shall be deposited into

1527 the General Fund.

1528 ~~[(f)]~~ (e) This Subsection ~~[(9)]~~ (10) does not prohibit a person who obtains information  
1529 from the state electronic verification system under Subsection (2)(a), (c), or (f) from:

1530 (i) including the information in the person's medical chart or file for access by a  
1531 person authorized to review the medical chart or file;

1532 (ii) providing the information to a person in accordance with the requirements of the  
1533 Health Insurance Portability and Accountability Act of 1996; or

1534 (iii) discussing or sharing that information about the patient with the patient.

1535 (11) A law enforcement officer who uses the database used by law enforcement to access  
1536 information in the electronic verification system for a reason that is not the  
1537 administration of criminal justice is guilty of a class B misdemeanor.

1538 Section 13. Section **26B-4-213** is amended to read:

1539 **26B-4-213 . Medical cannabis patient card -- Medical cannabis guardian card --**  
1540 **Conditional medical cannabis card -- Application -- Fees -- Studies.**

1541 (1)(a) Subject to Section 26B-4-246, within 15 days after the day on which an individual  
1542 who satisfies the eligibility criteria in this section or Section 26B-4-214 submits an  
1543 application in accordance with this section or Section 26B-4-214, the department shall[:]  
1544 issue the appropriate card to the individual for which the individual applied.

1545 ~~[(i) issue a medical cannabis patient card to an individual described in Subsection~~  
1546 ~~(2)(a);]~~

1547 ~~[(ii) issue a medical cannabis guardian card to an individual described in Subsection~~  
1548 ~~(2)(b);]~~

1549 ~~[(iii) issue a provisional patient card to a minor described in Subsection (2)(c); and]~~

1550 ~~[(iv) issue a medical cannabis caregiver card to an individual described in Subsection~~  
1551 ~~26B-4-214(4).]~~

1552 (b)(i) Upon the entry of a recommending medical provider's medical cannabis  
1553 recommendation for a patient in the state electronic verification system, either by  
1554 the provider or the provider's employee or by a medical cannabis pharmacy  
1555 medical provider or medical cannabis pharmacy in accordance with Subsection  
1556 4-41a-1101(10)(a), the department shall issue to the patient an electronic  
1557 conditional medical cannabis card, in accordance with this Subsection (1)(b).

1558 (ii) A conditional medical cannabis card is valid for the lesser of:

1559 (A) 60 days; or

1560 (B) the day on which the department completes the department's review and issues

1561 a medical cannabis card under Subsection (1)(a), denies the patient's medical  
1562 cannabis card application, or revokes the conditional medical cannabis card  
1563 under Subsection (8).

1564 (iii) The department may issue a conditional medical cannabis card to an individual  
1565 applying for a medical cannabis patient card for which approval of the  
1566 Compassionate Use Board is not required.

1567 (iv) An individual described in Subsection (1)(b)(iii) has the rights, restrictions, and  
1568 obligations under law applicable to a holder of the medical cannabis card for  
1569 which the individual applies and for which the department issues the conditional  
1570 medical cannabis card.

1571 (2)(a) An individual is eligible for a medical cannabis patient card if:

1572 (i)(A) the individual is at least 21 years old; or

1573 (B) the individual is 18, 19, or 20 years old, the individual petitions the  
1574 Compassionate Use Board under Section 26B-1-421, and the Compassionate  
1575 Use Board recommends department approval of the petition;

1576 (ii) the individual is a Utah resident;

1577 (iii) the individual's recommending medical provider recommends treatment with  
1578 medical cannabis in accordance with Subsection (4);

1579 (iv) the individual signs an acknowledgment stating that the individual received the  
1580 information described in Subsection (9); and

1581 (v) the individual pays to the department a fee in an amount that, subject to  
1582 Subsection 26B-1-310(5), the department sets in accordance with Section  
1583 63J-1-504.

1584 (b)(i) An individual is eligible for a medical cannabis guardian card if the individual:

1585 (A) is at least 18 years old;

1586 (B) is a Utah resident;

1587 (C)(I) is the parent or legal guardian of a minor for whom the minor's  
1588 recommending medical provider recommends a medical cannabis treatment,  
1589 the individual petitions the Compassionate Use Board under Section  
1590 26B-1-421, and the Compassionate Use Board recommends department  
1591 approval of the petition; or

1592 (II) is the legal guardian of an incapacitated adult and provides acceptable  
1593 proof of guardianship to the department;

1594 (D) the individual signs an acknowledgment stating that the individual received

- 1595 the information described in Subsection (9); and
- 1596 (E) pays to the department a fee in an amount that, subject to Subsection
- 1597 26B-1-310(5), the department sets in accordance with Section 63J-1-504, plus
- 1598 the cost of the criminal background check described in Section 26B-4-215.
- 1599 (ii) The department shall notify the Department of Public Safety of each individual
- 1600 that the department registers for a medical cannabis guardian card.
- 1601 (c)(i) A minor is eligible for a provisional patient card if:
- 1602 (A) the minor has a qualifying condition;
- 1603 (B) the minor's recommending medical provider recommends a medical cannabis
- 1604 treatment to address the minor's qualifying condition;
- 1605 (C) one of the minor's parents or legal guardians petitions the Compassionate Use
- 1606 Board under Section 26B-1-421, and the Compassionate Use Board
- 1607 recommends department approval of the petition; and
- 1608 (D) the minor's parent or legal guardian is eligible for a medical cannabis guardian
- 1609 card under Subsection (2)(b) or designates a caregiver under Subsection (2)(d)
- 1610 who is eligible for a medical cannabis caregiver card under Section 26B-4-214.
- 1611 (ii) The department shall automatically issue a provisional patient card to the minor
- 1612 described in Subsection (2)(c)(i) at the same time the department issues a medical
- 1613 cannabis guardian card to the minor's parent or legal guardian.
- 1614 (d) If the parent or legal guardian [~~of a minor described in Subsections (2)(e)(i)(A)~~
- 1615 ~~through (C)] does not qualify for a medical cannabis guardian card under Subsection~~
- 1616 (2)(b), the parent or legal guardian may designate up to two caregivers in accordance
- 1617 with Subsection 26B-4-214(1)(c) [~~to ensure that the minor has adequate and safe~~
- 1618 ~~access to the recommended medical cannabis treatment]~~.
- 1619 (e) The department shall issue a provisional patient card to an incapacitated adult if:
- 1620 (i) the incapacitated adult's legal guardian qualifies for a medical cannabis guardian
- 1621 card under Subsection (2)(b) or designates a caregiver under Subsection (2)(d)
- 1622 who is eligible for a medical cannabis caregiver card under Section 26B-4-214;
- 1623 and
- 1624 (ii) the individual's recommending medical provider recommends treatment with
- 1625 medical cannabis in accordance with Subsection (4).
- 1626 (3)(a) An individual who is eligible for a medical cannabis card described in Subsection
- 1627 (2)(a) or (b) shall submit an application for a medical cannabis card to the department:
- 1628 (i) through an electronic application connected to the state electronic verification

- 1629 system;
- 1630 (ii) with the recommending medical provider; and
- 1631 (iii) with information including:
- 1632 (A) the applicant's name, gender, age, and address;
- 1633 (B) the number of the applicant's government issued photo identification;
- 1634 (C) for a medical cannabis guardian card, the name, gender, and age of the [minor]
- 1635 individual receiving a medical cannabis treatment under the cardholder's
- 1636 medical cannabis guardian card; and
- 1637 (D) for a provisional patient card, the name of the [minor's]-parent or legal
- 1638 guardian who holds the associated medical cannabis guardian card.
- 1639 (b)(i) If a recommending medical provider determines that, because of age, illness, or
- 1640 disability, a medical cannabis patient cardholder requires assistance in
- 1641 administering the medical cannabis treatment that the recommending medical
- 1642 provider recommends, the recommending medical provider may indicate the
- 1643 cardholder's need in the state electronic verification system, either directly or
- 1644 through the order described in Subsections 26B-4-204(1)(b) and (c).
- 1645 (ii) If a recommending medical provider makes the indication described in
- 1646 Subsection (3)(b)(i):
- 1647 (A) the department shall add a label to the relevant medical cannabis patient card
- 1648 indicating the cardholder's need for assistance;
- 1649 (B) any adult who is 18 years old or older and who is physically present with the
- 1650 cardholder at the time the cardholder needs to use the recommended medical
- 1651 cannabis treatment may handle the medical cannabis treatment and any
- 1652 associated medical cannabis device as needed to assist the cardholder in
- 1653 administering the recommended medical cannabis treatment; and
- 1654 (C) an individual of any age who is physically present with the cardholder in the
- 1655 event of an emergency medical condition, as that term is defined in Section
- 1656 31A-1-301, may handle the medical cannabis treatment and any associated
- 1657 medical cannabis device as needed to assist the cardholder in administering the
- 1658 recommended medical cannabis treatment.
- 1659 (iii) A non-cardholding individual acting under Subsection (3)(b)(ii)(B) or (C) may
- 1660 not:
- 1661 (A) ingest or inhale medical cannabis;
- 1662 (B) possess, transport, or handle medical cannabis or a medical cannabis device

1663 outside of the immediate area where the cardholder is present or with an intent  
1664 other than to provide assistance to the cardholder; or  
1665 (C) possess, transport, or handle medical cannabis or a medical cannabis device  
1666 when the cardholder is not in the process of being dosed with medical cannabis.

1667 (4)(a) Except as provided in Subsection (4)(b), a recommending medical provider may  
1668 not recommend medical cannabis to a patient through a virtual visit.

1669 (b) A recommending medical provider may recommend medical cannabis to a patient  
1670 through a virtual visit if the patient:

1671 (i) is on hospice or has a terminal illness according to the patient's medical provider;

1672 (ii) is a resident of an assisted living facility, as defined in Section 26B-2-201, or a  
1673 nursing care facility, as defined in Section 26B-2-201;

1674 (iii) has previously received a medical cannabis recommendation from the  
1675 recommending medical provider through a face-to-face visit; or

1676 (iv) is a current patient of the recommending medical provider and has met with the  
1677 recommending medical provider face-to-face previously.

1678 (c) A recommending medical provider shall:

1679 (i) before recommending or renewing a recommendation for medical cannabis [~~in a~~  
1680 ~~medicinal dosage form or a cannabis product in a medicinal dosage form~~]:

1681 (A) verify the patient's and, for a minor patient, the minor patient's parent or legal  
1682 guardian's government issued photo identification described in Subsection  
1683 (3)(a);

1684 (B) review any record related to the patient and, for a minor patient, the patient's  
1685 parent or legal guardian accessible to the recommending medical provider  
1686 including in the controlled substance database created in Section 58-37f-201;  
1687 and

1688 (C) consider the recommendation in light of the patient's qualifying condition,  
1689 history of substance use or opioid use disorder, and history of medical cannabis  
1690 and controlled substance use during a visit with the patient; and

1691 (ii) state in the recommending medical provider's recommendation that the patient:

1692 (A) suffers from a qualifying condition, including the type of qualifying condition;  
1693 and

1694 (B) may benefit from treatment with [~~cannabis in a medicinal dosage form or a~~  
1695 ~~cannabis product in a medicinal dosage form~~] medical cannabis.

1696 (5)(a) Except as provided in Subsection (5)(b) or (c), a medical cannabis card that the

- 1697 department issues under this section is valid for the lesser of:
- 1698 (i) an amount of time that the recommending medical provider determines; or
- 1699 (ii) one year from the day the card is issued.
- 1700 (b)(i) A medical cannabis card that the department issues in relation to a terminal
- 1701 illness described in Section 26B-4-203 expires after one year.
- 1702 (ii) The recommending medical provider may revoke a recommendation that the
- 1703 provider made in relation to a terminal illness described in Section 26B-4-203 if
- 1704 the medical cannabis cardholder no longer has the terminal illness.
- 1705 (c) A medical cannabis card that the department issues in relation to acute pain as
- 1706 described in Section 26B-4-203 expires 30 days after the day on which the
- 1707 department first issues a conditional or full medical cannabis card.
- 1708 (6)(a) A medical cannabis patient card or a medical cannabis guardian card is renewable
- 1709 if:
- 1710 (i) at the time of renewal, the cardholder meets the requirements of Subsection (2)(a)
- 1711 or (b); or
- 1712 (ii) the cardholder received the medical cannabis card through the recommendation of
- 1713 the Compassionate Use Board under Section 26B-1-421.
- 1714 (b) The recommending medical provider who made the underlying recommendation for
- 1715 the card of a cardholder described in Subsection (6)(a) may renew the cardholder's
- 1716 card through phone or video conference with the cardholder, at the recommending
- 1717 medical provider's discretion.
- 1718 (c) Before having access to a renewed card, a cardholder under Subsection (2)(a) or (b)
- 1719 shall pay to the department a renewal fee in an amount that:
- 1720 (i) subject to Subsection 26B-1-310(5), the department sets in accordance with
- 1721 Section 63J-1-504; and
- 1722 (ii) may not exceed the cost of the relatively lower administrative burden of renewal
- 1723 in comparison to the original application process.
- 1724 (d) If a minor meets the requirements of Subsection (2)(c), the minor's provisional
- 1725 patient card renews automatically at the time the minor's parent or legal guardian
- 1726 renews the parent or legal guardian's associated medical cannabis guardian card.
- 1727 (7)(a) A cardholder under this section shall carry the cardholder's valid medical cannabis
- 1728 card with the patient's name.
- 1729 (b)(i) A medical cannabis patient cardholder or a provisional patient cardholder may
- 1730 purchase, in accordance with this part and the recommendation underlying the

- 1731 card, [~~cannabis in a medicinal dosage form, a cannabis product in a medicinal~~  
1732 ~~dosage form,]~~ medical cannabis or a medical cannabis device.
- 1733 (ii) A cardholder under this section may possess or transport, in accordance with this  
1734 part and the recommendation underlying the card, [~~cannabis in a medicinal dosage~~  
1735 ~~form, a cannabis product in a medicinal dosage form,]~~ medical cannabis or a  
1736 medical cannabis device.
- 1737 (iii) To address the qualifying condition underlying the medical cannabis treatment  
1738 recommendation:
- 1739 (A) a medical cannabis patient cardholder or a provisional patient cardholder may  
1740 use medical cannabis or a medical cannabis device; and
- 1741 (B) a medical cannabis guardian cardholder may assist the associated provisional  
1742 patient cardholder with the use of medical cannabis or a medical cannabis  
1743 device.
- 1744 (8)(a) The department may revoke a medical cannabis card that the department issues  
1745 under this section if:
- 1746 (i) the recommending medical provider withdraws the medical provider's  
1747 recommendation for medical cannabis; or
- 1748 (ii) the cardholder:
- 1749 (A) violates this part; or
- 1750 (B) is convicted under state or federal law of, after March 17, 2021, a drug  
1751 distribution offense.
- 1752 (b) The department may not refuse to issue a medical cannabis card to a patient solely  
1753 based on a prior revocation under Subsection (8)(a)(i).
- 1754 (9) The department shall establish by rule, in accordance with Title 63G, Chapter 3, Utah  
1755 Administrative Rulemaking Act, a process to provide information regarding the  
1756 following to an individual receiving a medical cannabis card:
- 1757 (a) risks associated with medical cannabis treatment;
- 1758 (b) the fact that a condition's listing as a qualifying condition does not suggest that  
1759 medical cannabis treatment is an effective treatment or cure for that condition, as  
1760 described in Subsection 26B-4-203(1); and
- 1761 (c) other relevant warnings and safety information that the department determines.
- 1762 (10) The department may establish procedures by rule, in accordance with Title 63G,  
1763 Chapter 3, Utah Administrative Rulemaking Act, to implement the application and  
1764 issuance provisions of this section.

- 1765 (11)(a) The department shall establish by rule, in accordance with Title 63G, Chapter 3,  
1766 Utah Administrative Rulemaking Act, a process to allow an individual from another  
1767 state to register with the department in order to purchase medical cannabis or a  
1768 medical cannabis device from a medical cannabis pharmacy while the individual is  
1769 visiting the state.
- 1770 (b) The department may only provide the registration process described in Subsection  
1771 (11)(a):
- 1772 (i) to a nonresident patient; and
  - 1773 (ii) for no more than two visitation periods per calendar year of up to 21 calendar  
1774 days per visitation period.
- 1775 (12)(a) A person may submit to the department a request to conduct a research study  
1776 using medical cannabis cardholder data that the state electronic verification system  
1777 contains.
- 1778 (b) The department shall review a request described in Subsection (12)(a) to determine  
1779 whether an institutional review board, as that term is defined in Section 26B-4-201,  
1780 could approve the research study.
- 1781 (c) At the time an individual applies for a medical cannabis card, the department shall  
1782 notify the individual:
- 1783 (i) of how the individual's information will be used as a cardholder;
  - 1784 (ii) that by applying for a medical cannabis card, unless the individual withdraws  
1785 consent under Subsection (12)(d), the individual consents to the use of the  
1786 individual's information for external research; and
  - 1787 (iii) that the individual may withdraw consent for the use of the individual's  
1788 information for external research at any time, including at the time of application.
- 1789 (d) An applicant may, through the medical cannabis card application, and a medical  
1790 cannabis cardholder may, through the state central patient portal, withdraw the  
1791 applicant's or cardholder's consent to participate in external research at any time.
- 1792 (e) The department may release, for the purposes of a study described in this Subsection  
1793 (12), information about a cardholder under this section who consents to participate  
1794 under Subsection (12)(c).
- 1795 (f) If an individual withdraws consent under Subsection (12)(d), the withdrawal of  
1796 consent:
- 1797 (i) applies to external research that is initiated after the withdrawal of consent; and
  - 1798 (ii) does not apply to research that was initiated before the withdrawal of consent.

1799 (g) The department may establish standards for a medical research study's validity, by  
 1800 rule made in accordance with Title 63G, Chapter 3, Utah Administrative Rulemaking  
 1801 Act.

1802 (13) The department shall record the issuance or revocation of a medical cannabis card  
 1803 under this section in the controlled substance database.

1804 Section 14. Section **26B-4-214** is amended to read:

1805 **26B-4-214 . Medical cannabis caregiver card -- Registration -- Renewal --**

1806 **Revocation.**

1807 (1)(a) A [~~cardholder described in Section 26B-4-213~~] medical cannabis patient  
 1808 cardholder or medical cannabis guardian cardholder may designate up to two  
 1809 individuals, or an individual and a facility in accordance with Subsection (1)(b), to  
 1810 serve as a designated caregiver for the cardholder.

1811 (b)(i) A [~~cardholder described in Section 26B-4-213~~] medical cannabis patient  
 1812 cardholder or medical cannabis guardian cardholder may designate one of the  
 1813 following types of facilities as one of the caregivers described in Subsection (1)(a):

1814 (A) for a patient or resident, an assisted living facility, as that term is defined in  
 1815 Section 26B-2-201;

1816 (B) for a patient or resident, a nursing care facility, as that term is defined in  
 1817 Section 26B-2-201; or

1818 (C) for a patient, a general acute hospital, as that term is defined in Section  
 1819 26B-2-201.

1820 (ii) A facility may:

1821 (A) assign one or more employees to assist patients with medical cannabis  
 1822 treatment under the caregiver designation described in this Subsection (1)(b);  
 1823 and

1824 (B) receive a medical cannabis shipment from a medical cannabis pharmacy or a  
 1825 medical cannabis courier on behalf of the medical cannabis cardholder within  
 1826 the facility who designated the facility as a caregiver.

1827 (iii) The department shall make rules to regulate the practice of facilities and facility  
 1828 employees serving as designated caregivers under this Subsection (1)(b).

1829 (c) A parent or legal guardian described in Subsection 26B-4-213(2)(d), in consultation  
 1830 with the minor and the minor's recommending medical provider, may designate up to  
 1831 two individuals to serve as [a] designated [~~caregiver~~] caregivers for the minor, if the  
 1832 department determines that the parent or legal guardian is not eligible for a medical

- 1833 cannabis guardian card under Section 26B-4-213.
- 1834 (d)(i) Upon the entry of a caregiver designation under Subsection (1)(c) by a patient  
1835 with a terminal illness described in Section 26B-4-203, the department shall issue  
1836 to the designated caregiver an electronic conditional medical cannabis caregiver  
1837 card, in accordance with this Subsection (1)(d).
- 1838 (ii) A conditional medical cannabis caregiver card is valid for the lesser of:
- 1839 (A) 60 days; or
- 1840 (B) the day on which the department completes the department's review and issues  
1841 a medical cannabis caregiver card under Subsection (1)(a), denies the patient's  
1842 medical cannabis caregiver card application, or revokes the conditional  
1843 medical cannabis caregiver card under Section 26B-4-246.
- 1844 (iii) The department may issue a conditional medical cannabis card to an individual  
1845 applying for a medical cannabis patient card for which approval of the  
1846 Compassionate Use Board is not required.
- 1847 (iv) An individual described in Subsection (1)(b)(iii) has the rights, restrictions, and  
1848 obligations under law applicable to a holder of the medical cannabis card for  
1849 which the individual applies and for which the department issues the conditional  
1850 medical cannabis card.
- 1851 (2) An individual that the department registers as a designated caregiver under this section  
1852 and a facility described in Subsection (1)(b):
- 1853 (a) for an individual designated caregiver, may carry a valid medical cannabis caregiver  
1854 card;
- 1855 (b) in accordance with this part, may purchase, possess, transport, or assist the patient in  
1856 the use of medical cannabis or a medical cannabis device on behalf of the designating  
1857 medical cannabis cardholder;
- 1858 (c) may not charge a fee to an individual to act as the individual's designated caregiver  
1859 or for a service that the designated caregiver provides in relation to the role as a  
1860 designated caregiver; and
- 1861 (d) may accept reimbursement from the designating medical cannabis cardholder for  
1862 direct costs the designated caregiver incurs for assisting with the designating  
1863 cardholder's medicinal use of cannabis.
- 1864 (3)(a) The department shall:
- 1865 (i) within 15 days after the day on which an individual submits an application in  
1866 compliance with this section, issue a medical cannabis card to the applicant if the

- 1867 applicant:
- 1868 (A) is designated as a caregiver under Subsection (1);
- 1869 (B) is eligible for a medical cannabis caregiver card under Subsection (4); and
- 1870 (C) complies with this section; and
- 1871 (ii) notify the Department of Public Safety of each individual that the department
- 1872 registers as a designated caregiver.
- 1873 (b) The department shall ensure that a medical cannabis caregiver card contains the
- 1874 information described in Subsections (5)(b) and (3)(c)(i).
- 1875 (c) If a [~~cardholder described in Section 26B-4-213~~] medical cannabis patient cardholder
- 1876 or medical cannabis guardian cardholder designates an individual as a caregiver who
- 1877 already holds a medical cannabis caregiver card, the individual with the medical
- 1878 cannabis caregiver card:
- 1879 (i) shall report to the department the information required of applicants under
- 1880 Subsection (5)(b) regarding the new designation;
- 1881 (ii) if the individual makes the report described in Subsection (3)(c)(i), is not required
- 1882 to file an application for another medical cannabis caregiver card;
- 1883 (iii) may receive an additional medical cannabis caregiver card in relation to each
- 1884 additional medical cannabis patient who designates the caregiver; and
- 1885 (iv) is not subject to an additional background check.
- 1886 (4) An individual is eligible for a medical cannabis caregiver card if the individual:
- 1887 (a) is at least 21 years old;
- 1888 (b) is a Utah resident;
- 1889 (c) pays to the department a fee in an amount that, subject to Subsection 26B-1-310(5),
- 1890 the department sets in accordance with Section 63J-1-504, plus the cost of the
- 1891 criminal background check described in Section 26B-4-215; and
- 1892 (d) signs an acknowledgment stating that the applicant received the information
- 1893 described in Subsection 26B-4-213(9).
- 1894 (5) An eligible applicant for a medical cannabis caregiver card shall:
- 1895 (a) submit an application for a medical cannabis caregiver card to the department
- 1896 through an electronic application connected to the state electronic verification
- 1897 system; and
- 1898 (b) submit the following information in the application described in Subsection (5)(a):
- 1899 (i) the applicant's name, gender, age, and address;
- 1900 (ii) the name, gender, age, and address of the [~~cardholder described in Section~~

- 1901 26B-4-213] medical cannabis patient cardholder or medical cannabis guardian  
 1902 cardholder who designated the applicant;
- 1903 (iii) if a medical cannabis guardian cardholder designated the caregiver, the name,  
 1904 gender, and age of the minor receiving a medical cannabis treatment in relation to  
 1905 the medical cannabis guardian cardholder; and
- 1906 (iv) any additional information that the department requests to assist in matching the  
 1907 application with the designating medical cannabis patient.
- 1908 (6) [~~Except as provided in Subsection (6)(b), a-~~] A medical cannabis caregiver card that the  
 1909 department issues under this section is valid for the lesser of:
- 1910 (a) an amount of time that the [~~cardholder described in Section 26B-4-213]~~ medical  
 1911 cannabis patient cardholder or medical cannabis guardian cardholder who designated  
 1912 the caregiver determines; or
- 1913 (b) the amount of time remaining before the card of the [~~cardholder described in Section~~  
 1914 ~~26B-4-213]~~ medical cannabis patient cardholder or medical cannabis guardian  
 1915 cardholder expires.
- 1916 (7)(a) If a designated caregiver meets the requirements of Subsection (4), the designated  
 1917 caregiver's medical cannabis caregiver card renews automatically at the time the [~~cardholder described in Section 26B-4-213]~~ medical cannabis patient cardholder or  
 1918 medical cannabis guardian cardholder who designated the caregiver:
- 1919 (i) renews the cardholder's card; and  
 1920 (ii) renews the caregiver's designation, in accordance with Subsection (7)(b).
- 1921 (b) The department shall provide a method in the card renewal process to allow a [~~cardholder described in Section 26B-4-213]~~ medical cannabis patient cardholder or  
 1922 medical cannabis guardian cardholder who has designated a caregiver to:
- 1923 (i) signify that the cardholder renews the caregiver's designation;  
 1924 (ii) remove a caregiver's designation; or  
 1925 (iii) designate a new caregiver.
- 1926 (8) The department shall record the issuance or revocation of a medical cannabis card under  
 1927 this section in the controlled substance database.
- 1928 Section 15. Section **63I-2-236** is amended to read:  
 1929 **63I-2-236 . Repeal dates: Title 36.**
- 1930 (1) Section 36-12-8.2, Medical cannabis governance structure working group, is repealed  
 1931 July 1, [2026] 2027.
- 1932 (2) Section 36-29-109, Utah Broadband Center Advisory Commission, is repealed  
 1933

1935            November 30, 2027.

1936            Section 16. **Effective Date.**

1937            This bill takes effect on May 6, 2026.